EP3349784A1 - Glycotargeting therapeutics - Google Patents
Glycotargeting therapeuticsInfo
- Publication number
- EP3349784A1 EP3349784A1 EP16778870.2A EP16778870A EP3349784A1 EP 3349784 A1 EP3349784 A1 EP 3349784A1 EP 16778870 A EP16778870 A EP 16778870A EP 3349784 A1 EP3349784 A1 EP 3349784A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- compound
- antigen
- immune response
- integer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 65
- 239000000427 antigen Substances 0.000 claims abstract description 346
- 108091007433 antigens Proteins 0.000 claims abstract description 315
- 102000036639 antigens Human genes 0.000 claims abstract description 315
- 239000000203 mixture Substances 0.000 claims abstract description 239
- 230000028993 immune response Effects 0.000 claims abstract description 138
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 99
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 98
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 98
- 238000000034 method Methods 0.000 claims abstract description 75
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 62
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 55
- 210000004185 liver Anatomy 0.000 claims abstract description 49
- 238000011282 treatment Methods 0.000 claims abstract description 43
- 206010052779 Transplant rejections Diseases 0.000 claims abstract description 25
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 21
- 150000001875 compounds Chemical class 0.000 claims description 242
- -1 seclain Proteins 0.000 claims description 173
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 136
- 235000018102 proteins Nutrition 0.000 claims description 97
- 125000005647 linker group Chemical group 0.000 claims description 90
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 82
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 81
- 229930182830 galactose Natural products 0.000 claims description 81
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims description 80
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims description 78
- 229960003082 galactose Drugs 0.000 claims description 77
- 239000012634 fragment Substances 0.000 claims description 72
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 72
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 68
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 66
- 229960001031 glucose Drugs 0.000 claims description 66
- 239000008103 glucose Substances 0.000 claims description 65
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 61
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 61
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 60
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 60
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 58
- 229960002442 glucosamine Drugs 0.000 claims description 58
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 51
- 108010061711 Gliadin Proteins 0.000 claims description 46
- 239000003446 ligand Substances 0.000 claims description 46
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 45
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 45
- 206010020751 Hypersensitivity Diseases 0.000 claims description 42
- 208000026935 allergic disease Diseases 0.000 claims description 41
- 108090001061 Insulin Proteins 0.000 claims description 37
- 102000004877 Insulin Human genes 0.000 claims description 37
- 229940125396 insulin Drugs 0.000 claims description 36
- 230000003614 tolerogenic effect Effects 0.000 claims description 33
- 241001465754 Metazoa Species 0.000 claims description 31
- 235000013305 food Nutrition 0.000 claims description 29
- 239000013566 allergen Substances 0.000 claims description 28
- 108010024976 Asparaginase Proteins 0.000 claims description 25
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 25
- 108010076282 Factor IX Proteins 0.000 claims description 25
- 230000008685 targeting Effects 0.000 claims description 25
- 108010054218 Factor VIII Proteins 0.000 claims description 24
- 102000001690 Factor VIII Human genes 0.000 claims description 24
- 229960004222 factor ix Drugs 0.000 claims description 24
- 229960000301 factor viii Drugs 0.000 claims description 24
- 229920000642 polymer Polymers 0.000 claims description 24
- 108010068370 Glutens Proteins 0.000 claims description 22
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 claims description 22
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 claims description 22
- 230000007815 allergy Effects 0.000 claims description 22
- 229920005604 random copolymer Polymers 0.000 claims description 22
- 108010092464 Urate Oxidase Proteins 0.000 claims description 21
- 230000009610 hypersensitivity Effects 0.000 claims description 20
- 229920001223 polyethylene glycol Polymers 0.000 claims description 20
- 108010050792 glutenin Proteins 0.000 claims description 19
- 101710183587 Omega-gliadin Proteins 0.000 claims description 18
- 241000196324 Embryophyta Species 0.000 claims description 17
- 230000000890 antigenic effect Effects 0.000 claims description 17
- 230000001939 inductive effect Effects 0.000 claims description 17
- 229960003272 asparaginase Drugs 0.000 claims description 16
- 125000004076 pyridyl group Chemical group 0.000 claims description 16
- 102000015790 Asparaginase Human genes 0.000 claims description 15
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 15
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims description 15
- 201000006417 multiple sclerosis Diseases 0.000 claims description 15
- 102000047918 Myelin Basic Human genes 0.000 claims description 14
- 229920001577 copolymer Polymers 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 230000007613 environmental effect Effects 0.000 claims description 13
- 235000021312 gluten Nutrition 0.000 claims description 12
- 235000000346 sugar Nutrition 0.000 claims description 12
- 102100038247 Retinol-binding protein 3 Human genes 0.000 claims description 11
- 102000012002 Aquaporin 4 Human genes 0.000 claims description 10
- 108010036280 Aquaporin 4 Proteins 0.000 claims description 10
- 101710087459 Gamma-gliadin Proteins 0.000 claims description 10
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims description 10
- 102000055324 Myelin Proteolipid Human genes 0.000 claims description 10
- 101710094913 Myelin proteolipid protein Proteins 0.000 claims description 10
- 108010076181 Proinsulin Proteins 0.000 claims description 10
- 102000003425 Tyrosinase Human genes 0.000 claims description 10
- 108060008724 Tyrosinase Proteins 0.000 claims description 10
- 108010048996 interstitial retinol-binding protein Proteins 0.000 claims description 10
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 9
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims description 9
- 101710107068 Myelin basic protein Proteins 0.000 claims description 9
- 125000001931 aliphatic group Chemical group 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 108010066381 preproinsulin Proteins 0.000 claims description 9
- 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 claims description 8
- 108060006613 prolamin Proteins 0.000 claims description 8
- XXRYFVCIMARHRS-UHFFFAOYSA-N propan-2-yl n-dimethoxyphosphorylcarbamate Chemical compound COP(=O)(OC)NC(=O)OC(C)C XXRYFVCIMARHRS-UHFFFAOYSA-N 0.000 claims description 8
- 206010047642 Vitiligo Diseases 0.000 claims description 7
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 7
- 206010046851 Uveitis Diseases 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 101710186708 Agglutinin Proteins 0.000 claims description 5
- 235000003911 Arachis Nutrition 0.000 claims description 5
- 108010049003 Fibrinogen Proteins 0.000 claims description 5
- 102000008946 Fibrinogen Human genes 0.000 claims description 5
- 101710146024 Horcolin Proteins 0.000 claims description 5
- 108010063045 Lactoferrin Proteins 0.000 claims description 5
- 101710189395 Lectin Proteins 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 101710179758 Mannose-specific lectin Proteins 0.000 claims description 5
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 claims description 5
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 claims description 5
- 201000011152 Pemphigus Diseases 0.000 claims description 5
- 108010029485 Protein Isoforms Proteins 0.000 claims description 5
- 102000001708 Protein Isoforms Human genes 0.000 claims description 5
- 108010030743 Tropomyosin Proteins 0.000 claims description 5
- 102000005937 Tropomyosin Human genes 0.000 claims description 5
- 239000000910 agglutinin Substances 0.000 claims description 5
- 229940012952 fibrinogen Drugs 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 5
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 4
- 102100023804 Coagulation factor VII Human genes 0.000 claims description 4
- 108010023321 Factor VII Proteins 0.000 claims description 4
- 102000034337 acetylcholine receptors Human genes 0.000 claims description 4
- 229940012413 factor vii Drugs 0.000 claims description 4
- 102100036830 Annexin A9 Human genes 0.000 claims description 3
- 102000003916 Arrestin Human genes 0.000 claims description 3
- 108090000328 Arrestin Proteins 0.000 claims description 3
- 102000006375 Desmocollins Human genes 0.000 claims description 3
- 108010019063 Desmocollins Proteins 0.000 claims description 3
- 108010045579 Desmoglein 1 Proteins 0.000 claims description 3
- 102000007577 Desmoglein 3 Human genes 0.000 claims description 3
- 108010032035 Desmoglein 3 Proteins 0.000 claims description 3
- 102100034579 Desmoglein-1 Human genes 0.000 claims description 3
- 102100034573 Desmoglein-4 Human genes 0.000 claims description 3
- 101710183213 Desmoglein-4 Proteins 0.000 claims description 3
- 102000029792 Desmoplakin Human genes 0.000 claims description 3
- 108091000074 Desmoplakin Proteins 0.000 claims description 3
- 101000928294 Homo sapiens Annexin A9 Proteins 0.000 claims description 3
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 claims description 3
- 108010065472 Vimentin Proteins 0.000 claims description 3
- 230000007812 deficiency Effects 0.000 claims description 3
- 102000054078 gamma Catenin Human genes 0.000 claims description 3
- 108010084448 gamma Catenin Proteins 0.000 claims description 3
- 210000005048 vimentin Anatomy 0.000 claims description 3
- 102000000503 Collagen Type II Human genes 0.000 claims description 2
- 108010041390 Collagen Type II Proteins 0.000 claims description 2
- 241000587784 Pemphis Species 0.000 claims description 2
- 230000002207 retinal effect Effects 0.000 claims description 2
- 241000220438 Arachis Species 0.000 claims 1
- 102100032241 Lactotransferrin Human genes 0.000 claims 1
- 101710178358 Peptidoglycan-associated lipoprotein Proteins 0.000 claims 1
- 101710189920 Peptidyl-alpha-hydroxyglycine alpha-amidating lyase Proteins 0.000 claims 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 claims 1
- 102000013127 Vimentin Human genes 0.000 claims 1
- 230000006058 immune tolerance Effects 0.000 abstract description 13
- 230000006698 induction Effects 0.000 abstract description 13
- 230000002265 prevention Effects 0.000 abstract description 4
- 208000004262 Food Hypersensitivity Diseases 0.000 abstract description 3
- 206010016946 Food allergy Diseases 0.000 abstract description 3
- 235000020932 food allergy Nutrition 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 122
- 101000609767 Dromaius novaehollandiae Ovalbumin Proteins 0.000 description 99
- 210000004681 ovum Anatomy 0.000 description 99
- 238000006243 chemical reaction Methods 0.000 description 87
- 241000699670 Mus sp. Species 0.000 description 67
- 239000000243 solution Substances 0.000 description 64
- 102000004196 processed proteins & peptides Human genes 0.000 description 52
- 229920001184 polypeptide Polymers 0.000 description 47
- 210000001744 T-lymphocyte Anatomy 0.000 description 45
- 210000004027 cell Anatomy 0.000 description 42
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- 238000003756 stirring Methods 0.000 description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 230000027455 binding Effects 0.000 description 26
- 239000011780 sodium chloride Substances 0.000 description 26
- 150000001413 amino acids Chemical class 0.000 description 25
- 239000002904 solvent Substances 0.000 description 24
- 229940024606 amino acid Drugs 0.000 description 23
- 108010058846 Ovalbumin Proteins 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 22
- 229940092253 ovalbumin Drugs 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 21
- 201000010099 disease Diseases 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 20
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 18
- 108700023158 Phenylalanine ammonia-lyases Proteins 0.000 description 17
- 238000000746 purification Methods 0.000 description 16
- 101000662009 Homo sapiens UDP-N-acetylglucosamine pyrophosphorylase Proteins 0.000 description 15
- 102100037921 UDP-N-acetylglucosamine pyrophosphorylase Human genes 0.000 description 15
- 125000003277 amino group Chemical group 0.000 description 15
- 238000012512 characterization method Methods 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 210000003494 hepatocyte Anatomy 0.000 description 13
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 12
- 108010056760 agalsidase beta Proteins 0.000 description 12
- 210000000612 antigen-presenting cell Anatomy 0.000 description 12
- 210000001165 lymph node Anatomy 0.000 description 12
- 230000002062 proliferating effect Effects 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 238000001542 size-exclusion chromatography Methods 0.000 description 12
- 102100036255 Glucose-6-phosphatase 2 Human genes 0.000 description 11
- 108010049936 agalsidase alfa Proteins 0.000 description 11
- 229960001239 agalsidase alfa Drugs 0.000 description 11
- 229960004470 agalsidase beta Drugs 0.000 description 11
- 238000012217 deletion Methods 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- KUBARPMUNHKBIQ-VTHUDJRQSA-N eliglustat tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1 KUBARPMUNHKBIQ-VTHUDJRQSA-N 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 10
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 10
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 10
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 10
- 108010016076 Octreotide Proteins 0.000 description 10
- 229960000446 abciximab Drugs 0.000 description 10
- 229960002964 adalimumab Drugs 0.000 description 10
- 229960004593 alglucosidase alfa Drugs 0.000 description 10
- 230000021615 conjugation Effects 0.000 description 10
- 102000045921 human GAA Human genes 0.000 description 10
- 229960002486 laronidase Drugs 0.000 description 10
- 150000007523 nucleic acids Chemical group 0.000 description 10
- 229960002700 octreotide Drugs 0.000 description 10
- 108010084837 rasburicase Proteins 0.000 description 10
- 229960000424 rasburicase Drugs 0.000 description 10
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 10
- 108090000672 Annexin A5 Proteins 0.000 description 9
- 102000004121 Annexin A5 Human genes 0.000 description 9
- 208000015943 Coeliac disease Diseases 0.000 description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
- 102100035857 Glutamate decarboxylase 2 Human genes 0.000 description 9
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 108010024780 glutamate decarboxylase 2 Proteins 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 125000003396 thiol group Chemical group [H]S* 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 108010088751 Albumins Proteins 0.000 description 8
- 102000009027 Albumins Human genes 0.000 description 8
- 244000105624 Arachis hypogaea Species 0.000 description 8
- 101000693927 Canis lupus familiaris Albumin Proteins 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 101000930907 Homo sapiens Glucose-6-phosphatase 2 Proteins 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 102100022135 S-arrestin Human genes 0.000 description 8
- 101710117586 S-arrestin Proteins 0.000 description 8
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 230000007717 exclusion Effects 0.000 description 8
- 210000000987 immune system Anatomy 0.000 description 8
- 210000001865 kupffer cell Anatomy 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 7
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 7
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 description 7
- 230000002411 adverse Effects 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 238000001502 gel electrophoresis Methods 0.000 description 7
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 229940086542 triethylamine Drugs 0.000 description 7
- 101150075175 Asgr1 gene Proteins 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 241000282326 Felis catus Species 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000013557 residual solvent Substances 0.000 description 6
- 230000009870 specific binding Effects 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 5
- 101000987118 Homo sapiens Ran guanine nucleotide release factor Proteins 0.000 description 5
- 101710110798 Mannose-binding protein C Proteins 0.000 description 5
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 description 5
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 5
- 102100027976 Ran guanine nucleotide release factor Human genes 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 150000001720 carbohydrates Chemical group 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 5
- 108010058207 Anistreplase Proteins 0.000 description 4
- 235000017060 Arachis glabrata Nutrition 0.000 description 4
- 235000010777 Arachis hypogaea Nutrition 0.000 description 4
- 235000018262 Arachis monticola Nutrition 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 102000028180 Glycophorins Human genes 0.000 description 4
- 108091005250 Glycophorins Proteins 0.000 description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 4
- 208000031220 Hemophilia Diseases 0.000 description 4
- 208000009292 Hemophilia A Diseases 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 108010047761 Interferon-alpha Proteins 0.000 description 4
- 102000006992 Interferon-alpha Human genes 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 102000012174 Lactotransferrin Human genes 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 description 4
- 208000029310 Pediatric multiple sclerosis Diseases 0.000 description 4
- 206010034277 Pemphigoid Diseases 0.000 description 4
- 108010004729 Phycoerythrin Proteins 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 4
- 239000012346 acetyl chloride Substances 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 239000010432 diamond Substances 0.000 description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 108010049491 glucarpidase Proteins 0.000 description 4
- 229920000550 glycopolymer Polymers 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 229960000598 infliximab Drugs 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 229960005027 natalizumab Drugs 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 235000020232 peanut Nutrition 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 108010038379 sargramostim Proteins 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 229960003989 tocilizumab Drugs 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 3
- 208000026872 Addison Disease Diseases 0.000 description 3
- 206010001767 Alopecia universalis Diseases 0.000 description 3
- 208000002017 Autoimmune Hypophysitis Diseases 0.000 description 3
- 206010071576 Autoimmune aplastic anaemia Diseases 0.000 description 3
- 208000035900 Autoimmune polyendocrinopathy type 1 Diseases 0.000 description 3
- 208000023328 Basedow disease Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 101001011741 Bos taurus Insulin Proteins 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 240000006122 Chenopodium album Species 0.000 description 3
- 235000009344 Chenopodium album Nutrition 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 3
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 3
- 235000016623 Fragaria vesca Nutrition 0.000 description 3
- 240000009088 Fragaria x ananassa Species 0.000 description 3
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 3
- 102000006395 Globulins Human genes 0.000 description 3
- 108010044091 Globulins Proteins 0.000 description 3
- 101710172364 Glucose-6-phosphatase 2 Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000024869 Goodpasture syndrome Diseases 0.000 description 3
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 208000015023 Graves' disease Diseases 0.000 description 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 3
- 102000011845 Iodide peroxidase Human genes 0.000 description 3
- 108010036012 Iodide peroxidase Proteins 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 102000013519 Lipocalin-2 Human genes 0.000 description 3
- 108010051335 Lipocalin-2 Proteins 0.000 description 3
- 102000009151 Luteinizing Hormone Human genes 0.000 description 3
- 108010073521 Luteinizing Hormone Proteins 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 3
- 240000005561 Musa balbisiana Species 0.000 description 3
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 3
- 102000011195 Profilin Human genes 0.000 description 3
- 108050001408 Profilin Proteins 0.000 description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 description 3
- 201000009594 Systemic Scleroderma Diseases 0.000 description 3
- 206010042953 Systemic sclerosis Diseases 0.000 description 3
- 102100029337 Thyrotropin receptor Human genes 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 208000032775 alopecia universalis congenita Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 201000005000 autoimmune gastritis Diseases 0.000 description 3
- 201000009771 autoimmune polyendocrine syndrome type 1 Diseases 0.000 description 3
- 230000006472 autoimmune response Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 208000000594 bullous pemphigoid Diseases 0.000 description 3
- 229940009550 c1 esterase inhibitor Drugs 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 3
- 229960004579 epoetin beta Drugs 0.000 description 3
- 229940028334 follicle stimulating hormone Drugs 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 229940040129 luteinizing hormone Drugs 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 206010028417 myasthenia gravis Diseases 0.000 description 3
- 230000000505 pernicious effect Effects 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 206010036601 premature menopause Diseases 0.000 description 3
- 208000017942 premature ovarian failure 1 Diseases 0.000 description 3
- 208000011610 primary hypophysitis Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 208000004124 rheumatic heart disease Diseases 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229960002530 sargramostim Drugs 0.000 description 3
- 230000003393 splenic effect Effects 0.000 description 3
- 210000004500 stellate cell Anatomy 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NIJWSVFNELSKMF-UHFFFAOYSA-N (2,3,4,5,6-pentafluorophenyl) 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OC1=C(F)C(F)=C(F)C(F)=C1F NIJWSVFNELSKMF-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical compound OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 2
- 208000032194 Acute haemorrhagic leukoencephalitis Diseases 0.000 description 2
- 102000055025 Adenosine deaminases Human genes 0.000 description 2
- 102100038910 Alpha-enolase Human genes 0.000 description 2
- 235000013479 Amaranthus retroflexus Nutrition 0.000 description 2
- 235000004135 Amaranthus viridis Nutrition 0.000 description 2
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 102000004411 Antithrombin III Human genes 0.000 description 2
- 108090000935 Antithrombin III Proteins 0.000 description 2
- 240000007087 Apium graveolens Species 0.000 description 2
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 2
- 235000010591 Appio Nutrition 0.000 description 2
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 244000056139 Brassica cretica Species 0.000 description 2
- 235000003351 Brassica cretica Nutrition 0.000 description 2
- 235000003343 Brassica rupestris Nutrition 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 102100032378 Carboxypeptidase E Human genes 0.000 description 2
- 108010058255 Carboxypeptidase H Proteins 0.000 description 2
- 244000281762 Chenopodium ambrosioides Species 0.000 description 2
- 235000005484 Chenopodium berlandieri Nutrition 0.000 description 2
- 235000009332 Chenopodium rubrum Nutrition 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010044226 Class 8 Receptor-Like Protein Tyrosine Phosphatases Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 206010011258 Coxsackie myocarditis Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108010019673 Darbepoetin alfa Proteins 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- 108010074864 Factor XI Proteins 0.000 description 2
- 108010071289 Factor XIII Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 108010029961 Filgrastim Proteins 0.000 description 2
- 208000007465 Giant cell arteritis Diseases 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102100037907 High mobility group protein B1 Human genes 0.000 description 2
- 108010007267 Hirudins Proteins 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000825079 Homo sapiens Transcription factor SOX-13 Proteins 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 2
- 102000001974 Hyaluronidases Human genes 0.000 description 2
- 102100039093 Insulinoma-associated protein 2 Human genes 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
- 102100030694 Interleukin-11 Human genes 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 108010059881 Lactase Proteins 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108010010995 MART-1 Antigen Proteins 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 235000011430 Malus pumila Nutrition 0.000 description 2
- 235000015103 Malus silvestris Nutrition 0.000 description 2
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 2
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 2
- 102000007999 Nuclear Proteins Human genes 0.000 description 2
- 108010089610 Nuclear Proteins Proteins 0.000 description 2
- 102000019280 Pancreatic lipases Human genes 0.000 description 2
- 108050006759 Pancreatic lipases Proteins 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 108010068701 Pegloticase Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101800004937 Protein C Proteins 0.000 description 2
- 102000017975 Protein C Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 101800001700 Saposin-D Proteins 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 108010023197 Streptokinase Proteins 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 108010039185 Tenecteplase Proteins 0.000 description 2
- 108010049264 Teriparatide Proteins 0.000 description 2
- 108010034949 Thyroglobulin Proteins 0.000 description 2
- 102000009843 Thyroglobulin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010066702 Thyrotropin Alfa Proteins 0.000 description 2
- 102100022435 Transcription factor SOX-13 Human genes 0.000 description 2
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 2
- 208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 2
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 2
- 102100035071 Vimentin Human genes 0.000 description 2
- 229960003697 abatacept Drugs 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 229960003122 alglucerase Drugs 0.000 description 2
- 108010060162 alglucerase Proteins 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 229960004238 anakinra Drugs 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 229960000983 anistreplase Drugs 0.000 description 2
- 235000003484 annual ragweed Nutrition 0.000 description 2
- 230000001494 anti-thymocyte effect Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 2
- 229960005348 antithrombin iii Drugs 0.000 description 2
- 108010006523 asialoglycoprotein receptor Proteins 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 2
- 108010055460 bivalirudin Proteins 0.000 description 2
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 2
- 229960001500 bivalirudin Drugs 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 229940094657 botulinum toxin type a Drugs 0.000 description 2
- 235000006263 bur ragweed Nutrition 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 2
- 229960001838 canakinumab Drugs 0.000 description 2
- 229940077731 carbohydrate nutrients Drugs 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 229960003115 certolizumab pegol Drugs 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 235000003488 common ragweed Nutrition 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 229960001251 denosumab Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 108010034479 digoxin antibodies Fab fragments Proteins 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 125000000107 disulfanyl group Chemical group [*]SS[H] 0.000 description 2
- 229960000533 dornase alfa Drugs 0.000 description 2
- 108010067396 dornase alfa Proteins 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229960002224 eculizumab Drugs 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 108010002601 epoetin beta Proteins 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229940012444 factor xiii Drugs 0.000 description 2
- 229960004177 filgrastim Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 108010081934 follitropin beta Proteins 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 2
- 150000002256 galaktoses Chemical class 0.000 description 2
- 108010089296 galsulfase Proteins 0.000 description 2
- 229960005390 galsulfase Drugs 0.000 description 2
- 108010062699 gamma-Glutamyl Hydrolase Proteins 0.000 description 2
- 208000018090 giant cell myocarditis Diseases 0.000 description 2
- 229960004859 glucarpidase Drugs 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- 229960001743 golimumab Drugs 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 2
- 229960003911 histrelin acetate Drugs 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 229960002773 hyaluronidase Drugs 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 229960002127 imiglucerase Drugs 0.000 description 2
- 108010039650 imiglucerase Proteins 0.000 description 2
- 230000008004 immune attack Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
- 229940116108 lactase Drugs 0.000 description 2
- OTQCKZUSUGYWBD-BRHMIFOHSA-N lepirudin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 OTQCKZUSUGYWBD-BRHMIFOHSA-N 0.000 description 2
- 229960004408 lepirudin Drugs 0.000 description 2
- 108010053156 lipid transfer protein Proteins 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108010000594 mecasermin Proteins 0.000 description 2
- 229960001311 mecasermin Drugs 0.000 description 2
- 229960003613 mecasermin rinfabate Drugs 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000010460 mustard Nutrition 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- OKPYIWASQZGASP-UHFFFAOYSA-N n-(2-hydroxypropyl)-2-methylprop-2-enamide Chemical compound CC(O)CNC(=O)C(C)=C OKPYIWASQZGASP-UHFFFAOYSA-N 0.000 description 2
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229960002450 ofatumumab Drugs 0.000 description 2
- 108010046821 oprelvekin Proteins 0.000 description 2
- 229960001840 oprelvekin Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 2
- 108010001564 pegaspargase Proteins 0.000 description 2
- 108010044644 pegfilgrastim Proteins 0.000 description 2
- 229960001373 pegfilgrastim Drugs 0.000 description 2
- 229960001376 pegloticase Drugs 0.000 description 2
- 229960002995 pegvisomant Drugs 0.000 description 2
- 108700037519 pegvisomant Proteins 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 229960000856 protein c Drugs 0.000 description 2
- 230000001185 psoriatic effect Effects 0.000 description 2
- 235000009736 ragweed Nutrition 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 108010074523 rimabotulinumtoxinB Proteins 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 229960000532 sacrosidase Drugs 0.000 description 2
- 108010068072 salmon calcitonin Proteins 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 125000005629 sialic acid group Chemical group 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229960005202 streptokinase Drugs 0.000 description 2
- 206010043207 temporal arteritis Diseases 0.000 description 2
- 229960000216 tenecteplase Drugs 0.000 description 2
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 2
- 229960005460 teriparatide Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960002175 thyroglobulin Drugs 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 229960001612 trastuzumab emtansine Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- 229960003824 ustekinumab Drugs 0.000 description 2
- 229940110059 voraxaze Drugs 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- CBOJBBMQJBVCMW-NQZVPSPJSA-N (2r,3r,4r,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@@H](O)[C@H](O)CO CBOJBBMQJBVCMW-NQZVPSPJSA-N 0.000 description 1
- PFDKSMIROGGYHI-AWEZNQCLSA-N (2s)-2-amino-3-[4-(4-hydroxyphenoxy)-2-iodophenyl]propanoic acid Chemical compound C1=C(I)C(C[C@H](N)C(O)=O)=CC=C1OC1=CC=C(O)C=C1 PFDKSMIROGGYHI-AWEZNQCLSA-N 0.000 description 1
- XWKAVQKJQBISOL-ZETCQYMHSA-N (2s)-2-anilinopropanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CC=C1 XWKAVQKJQBISOL-ZETCQYMHSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- PCGDBWLKAYKBTN-UHFFFAOYSA-N 1,2-dithiole Chemical compound C1SSC=C1 PCGDBWLKAYKBTN-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- JYWKEVKEKOTYEX-UHFFFAOYSA-N 2,6-dibromo-4-chloroiminocyclohexa-2,5-dien-1-one Chemical compound ClN=C1C=C(Br)C(=O)C(Br)=C1 JYWKEVKEKOTYEX-UHFFFAOYSA-N 0.000 description 1
- LECMBPWEOVZHKN-UHFFFAOYSA-N 2-(2-chloroethoxy)ethanol Chemical compound OCCOCCCl LECMBPWEOVZHKN-UHFFFAOYSA-N 0.000 description 1
- VFQJPQFCQFQABO-UHFFFAOYSA-N 2-(disulfanyl)ethyl carbamate Chemical compound C(N)(OCCSS)=O VFQJPQFCQFQABO-UHFFFAOYSA-N 0.000 description 1
- AISZNMCRXZWVAT-UHFFFAOYSA-N 2-ethylsulfanylcarbothioylsulfanyl-2-methylpropanenitrile Chemical compound CCSC(=S)SC(C)(C)C#N AISZNMCRXZWVAT-UHFFFAOYSA-N 0.000 description 1
- VHSHLMUCYSAUQU-UHFFFAOYSA-N 2-hydroxypropyl methacrylate Chemical compound CC(O)COC(=O)C(C)=C VHSHLMUCYSAUQU-UHFFFAOYSA-N 0.000 description 1
- KHOZZXQUYJNHHB-BTVCFUMJSA-N 2-methylprop-2-enoic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical group CC(=C)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O KHOZZXQUYJNHHB-BTVCFUMJSA-N 0.000 description 1
- 102100024419 28S ribosomal protein S31, mitochondrial Human genes 0.000 description 1
- 101710119973 28S ribosomal protein S31, mitochondrial Proteins 0.000 description 1
- 101710168820 2S seed storage albumin protein Proteins 0.000 description 1
- UHBAPGWWRFVTFS-UHFFFAOYSA-N 4,4'-dipyridyl disulfide Chemical compound C=1C=NC=CC=1SSC1=CC=NC=C1 UHBAPGWWRFVTFS-UHFFFAOYSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 1
- 101710154868 60 kDa heat shock protein, mitochondrial Proteins 0.000 description 1
- 240000004731 Acer pseudoplatanus Species 0.000 description 1
- 235000002754 Acer pseudoplatanus Nutrition 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 244000298697 Actinidia deliciosa Species 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- ZHQQRIUYLMXDPP-SSDOTTSWSA-N Actinidine Natural products C1=NC=C(C)C2=C1[C@H](C)CC2 ZHQQRIUYLMXDPP-SSDOTTSWSA-N 0.000 description 1
- 102100022455 Adrenocorticotropic hormone receptor Human genes 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 241000223602 Alternaria alternata Species 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 240000004178 Anthoxanthum odoratum Species 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 101100268765 Arabidopsis thaliana 2A6 gene Proteins 0.000 description 1
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- 235000015701 Artemisia arbuscula Nutrition 0.000 description 1
- 235000002657 Artemisia tridentata Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 206010003402 Arthropod sting Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 241000123966 Blomia tropicalis Species 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 206010048396 Bone marrow transplant rejection Diseases 0.000 description 1
- QFUASLRDDMDJKT-UHFFFAOYSA-N C1(=CC=CC=C1)C(=S)SCC(=O)OCCOCCOCCOCCSSC1=NC=CC=C1 Chemical compound C1(=CC=CC=C1)C(=S)SCC(=O)OCCOCCOCCOCCSSC1=NC=CC=C1 QFUASLRDDMDJKT-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 description 1
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 1
- 102000013602 Cardiac Myosins Human genes 0.000 description 1
- 108010051609 Cardiac Myosins Proteins 0.000 description 1
- 241000723418 Carya Species 0.000 description 1
- 235000009025 Carya illinoensis Nutrition 0.000 description 1
- 244000068645 Carya illinoensis Species 0.000 description 1
- 241001655736 Catalpa bignonioides Species 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 102000010792 Chromogranin A Human genes 0.000 description 1
- 108010038447 Chromogranin A Proteins 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 241001149956 Cladosporium herbarum Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 108010026206 Conalbumin Proteins 0.000 description 1
- 108010074311 Corticotropin Receptors Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 101710151161 Cysteine proteinase inhibitor 1 Proteins 0.000 description 1
- 102100026278 Cysteine sulfinic acid decarboxylase Human genes 0.000 description 1
- 108010025905 Cystine-Knot Miniproteins Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241000238710 Dermatophagoides Species 0.000 description 1
- 108010055622 Dermatophagoides farinae antigen f 1 Proteins 0.000 description 1
- 241000238740 Dermatophagoides pteronyssinus Species 0.000 description 1
- 108010061629 Dermatophagoides pteronyssinus antigen p 1 Proteins 0.000 description 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 101000692709 Drosophila melanogaster Pre-intermoult gene 1 protein Proteins 0.000 description 1
- 101100285518 Drosophila melanogaster how gene Proteins 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 108010074604 Epoetin Alfa Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 241000238741 Euroglyphus maynei Species 0.000 description 1
- 102000008175 FSH Receptors Human genes 0.000 description 1
- 108010060374 FSH Receptors Proteins 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 102100031509 Fibrillin-1 Human genes 0.000 description 1
- 108010030229 Fibrillin-1 Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 108010073324 Glutaminase Proteins 0.000 description 1
- 102000009127 Glutaminase Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000003084 Graves Ophthalmopathy Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 108700010013 HMGB1 Proteins 0.000 description 1
- 101150021904 HMGB1 gene Proteins 0.000 description 1
- 108010055039 HSP47 Heat-Shock Proteins Proteins 0.000 description 1
- 102000001214 HSP47 Heat-Shock Proteins Human genes 0.000 description 1
- 108010014095 Histidine decarboxylase Proteins 0.000 description 1
- 102100037095 Histidine decarboxylase Human genes 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101000972485 Homo sapiens Lupus La protein Proteins 0.000 description 1
- 101000612994 Homo sapiens Tetraspanin-4 Proteins 0.000 description 1
- 101000664703 Homo sapiens Transcription factor SOX-10 Proteins 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102100039064 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102100027640 Islet cell autoantigen 1 Human genes 0.000 description 1
- 108050004848 Islet cell autoantigen 1 Proteins 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 101710090204 Kiwellin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 108010062867 Lenograstim Proteins 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010015372 Low Density Lipoprotein Receptor-Related Protein-2 Proteins 0.000 description 1
- 102100021922 Low-density lipoprotein receptor-related protein 2 Human genes 0.000 description 1
- 102100022742 Lupus La protein Human genes 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
- 101710130208 Melanocyte protein PMEL Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 102000018656 Mitogen Receptors Human genes 0.000 description 1
- 108010052006 Mitogen Receptors Proteins 0.000 description 1
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 101100096242 Mus musculus Sox9 gene Proteins 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 206010029888 Obliterative bronchiolitis Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 108010064983 Ovomucin Proteins 0.000 description 1
- 235000016499 Oxalis corniculata Nutrition 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 208000008267 Peanut Hypersensitivity Diseases 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 102000004590 Peripherins Human genes 0.000 description 1
- 108010003081 Peripherins Proteins 0.000 description 1
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 1
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 1
- 241000746983 Phleum pratense Species 0.000 description 1
- 208000000766 Pityriasis Lichenoides Diseases 0.000 description 1
- 206010048895 Pityriasis lichenoides et varioliformis acuta Diseases 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 235000006485 Platanus occidentalis Nutrition 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 102100030477 Plectin Human genes 0.000 description 1
- 108010054050 Plectin Proteins 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 208000004347 Postpericardiotomy Syndrome Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 238000011878 Proof-of-mechanism Methods 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012987 RAFT agent Substances 0.000 description 1
- 102000017143 RNA Polymerase I Human genes 0.000 description 1
- 108010013845 RNA Polymerase I Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 101710137010 Retinol-binding protein 3 Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000007001 Rumex acetosella Species 0.000 description 1
- 235000015761 Rumex acetosella Nutrition 0.000 description 1
- 235000015422 Rumex crispus ssp. crispus Nutrition 0.000 description 1
- 235000015426 Rumex crispus ssp. fauriei Nutrition 0.000 description 1
- 244000207667 Rumex vesicarius Species 0.000 description 1
- 108091006299 SLC2A2 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102000004598 Small Nuclear Ribonucleoproteins Human genes 0.000 description 1
- 108010003165 Small Nuclear Ribonucleoproteins Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 244000197975 Solidago virgaurea Species 0.000 description 1
- 235000000914 Solidago virgaurea Nutrition 0.000 description 1
- 102000014169 Steroid 21-Hydroxylase Human genes 0.000 description 1
- 108010011732 Steroid 21-Hydroxylase Proteins 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 102000003673 Symporters Human genes 0.000 description 1
- 108090000088 Symporters Proteins 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100040871 Tetraspanin-4 Human genes 0.000 description 1
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical group C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 1
- 101710203193 Thaumatin-like protein Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 102100038808 Transcription factor SOX-10 Human genes 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000005506 Tryptophan Hydroxylase Human genes 0.000 description 1
- 108010031944 Tryptophan Hydroxylase Proteins 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 241000611866 Tyrophagus putrescentiae Species 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 108091026838 U1 spliceosomal RNA Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241001106462 Ulmus Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 108090000350 actinidain Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 229940115115 aranesp Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000006424 autoimmune oophoritis Diseases 0.000 description 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 description 1
- 229940031422 benefix Drugs 0.000 description 1
- 229940075791 berinert Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 201000003848 bronchiolitis obliterans Diseases 0.000 description 1
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940105774 coagulation factor ix Drugs 0.000 description 1
- 229940105778 coagulation factor viii Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 229960005463 corifollitropin alfa Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000006334 disulfide bridging Effects 0.000 description 1
- 108010051081 dopachrome isomerase Proteins 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000009483 enzymatic pathway Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960003388 epoetin alfa Drugs 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229940014516 fabrazyme Drugs 0.000 description 1
- 102000005525 fibrillarin Human genes 0.000 description 1
- 108020002231 fibrillarin Proteins 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 108010006620 fodrin Proteins 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 229940001300 follistim Drugs 0.000 description 1
- 108010006578 follitropin alfa Proteins 0.000 description 1
- 229960005210 follitropin alfa Drugs 0.000 description 1
- 229960002907 follitropin beta Drugs 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002309 glutamines Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 102000028718 growth factor binding proteins Human genes 0.000 description 1
- 108091009353 growth factor binding proteins Proteins 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008102 immune modulation Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 102000028557 immunoglobulin binding proteins Human genes 0.000 description 1
- 108091009323 immunoglobulin binding proteins Proteins 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 229950000038 interferon alfa Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 108010045648 interferon omega 1 Proteins 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- LRDFRRGEGBBSRN-UHFFFAOYSA-N isobutyronitrile Chemical compound CC(C)C#N LRDFRRGEGBBSRN-UHFFFAOYSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 108010028309 kalinin Proteins 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229960002618 lenograstim Drugs 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940087875 leukine Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 108010052522 livetin Proteins 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 229960002332 lutropin alfa Drugs 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- IBIKHMZPHNKTHM-RDTXWAMCSA-N merck compound 25 Chemical compound C1C[C@@H](C(O)=O)[C@H](O)CN1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C1CC1 IBIKHMZPHNKTHM-RDTXWAMCSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229950003483 moroctocog alfa Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 201000009340 myotonic dystrophy type 1 Diseases 0.000 description 1
- XNSAINXGIQZQOO-UHFFFAOYSA-N n-[1-(2-carbamoylpyrrolidin-1-yl)-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide Chemical compound NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003163 nonacog alfa Drugs 0.000 description 1
- 229940112216 novoseven Drugs 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000000065 osmolyte Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000005047 peripherin Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 102000035123 post-translationally modified proteins Human genes 0.000 description 1
- 108091005626 post-translationally modified proteins Proteins 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000003214 pyranose derivatives Chemical class 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- QFYXSLAAXZTRLG-UHFFFAOYSA-N pyrrolidine-2,3-dione Chemical compound O=C1CCNC1=O QFYXSLAAXZTRLG-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108010013773 recombinant FVIIa Proteins 0.000 description 1
- 108010025139 recombinant factor VIII SQ Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 108010073863 saruplase Proteins 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 235000003513 sheep sorrel Nutrition 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- ZIQRIAYNHAKDDU-UHFFFAOYSA-N sodium;hydroiodide Chemical compound [Na].I ZIQRIAYNHAKDDU-UHFFFAOYSA-N 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 108010058198 sulfoalanine decarboxylase Proteins 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 108040006218 thyroid-stimulating hormone receptor activity proteins Proteins 0.000 description 1
- 229960000902 thyrotropin alfa Drugs 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- UPCXAARSWVHVLY-UHFFFAOYSA-N tris(2-hydroxyethyl)azanium;acetate Chemical compound CC(O)=O.OCCN(CCO)CCO UPCXAARSWVHVLY-UHFFFAOYSA-N 0.000 description 1
- 108010014402 tyrosinase-related protein-1 Proteins 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 108010055450 with HCG C-terminal peptide human follicle stimulating hormone Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
Definitions
- a Sequence Listing submitted as an ASCII text file via EFS-Web is hereby incorporated by reference in accordance with 35 U.S.C. ⁇ 1.52(e).
- the name of the ASCII text file for the Sequence Listing is ANOK001 P1WO_ST25.TXT, the date of creation of the ASCII text file is September 14, 2016, and the size of the ASCII text file is 47.4 KB.
- compositions that are useful in the treatment of transplant rejection, autoimmune disease, allergy (e.g., food allergy), and immune response against a therapeutic agent.
- compositions configured to target one or more cell types in the liver and, as a result, deliver an antigen to which tolerance is desired to the one or more cell types targeted, and thereby induce a processing of the antigen and induce immune tolerance to the antigen.
- the antigen as disclosed in more detail below, can comprise a therapeutic agent, a protein, a protein fragment, an antigenic mimic of a protein or protein fragment (e.g., a mimotope). Additional types of antigens are discussed in more detail below. Methods and uses of such compositions are also provided for, in several embodiments.
- a compound comprising Formula 1 :
- X comprises molecule comprising an antigenic region
- Y is of a linker moiety having a formula selected from the group consisting of:
- n is an integer from about 1 to 100
- present p is an integer from about 2 to 150
- present q is an integer from about 1 to 44
- present R 8 is -CH 2 - or -CH 2 -CH 2 -C(CH 3 )(CN)-
- present R 9 is a direct bond or -CH 2 -CH 2 — NH-C(O)-
- Z comprises a liver-targeting moiety.
- X is a protein or protein fragment comprising an antigenic region.
- Z is galactose, while in some embodiments Z is glucose.
- Z is galactosamine, while in some embodiments Z is glucosamine.
- the alpha anomer of glucose or galactose is used in the composition.
- the beta anomer of glucose or galactose is used in the composition.
- mixtures of the alpha and beta anomers are used, including optionally mixtures of glucose and galactose.
- Z is N-acetylgalactosamine, while in some embodiments Z is N-acetylglucosamine.
- the alpha anomer of glucosamine or galactosamine is used in the composition.
- the alpha anomer of glucosamine or galactosamine is used in the composition. In several embodiments, mixtures of the alpha and beta anomers are used, including optionally mixtures of glucosamine and galactosamine. Likewise, in several embodiments the alpha anomer, the beta anomer, or combinations of the alpha and beta anomers of N-acetylgalactosamine or N- acetylglucosamine. Combinations of any of the alpha or beta anomeric forms of any of the liver targeting sugars, and any combinations of the sugars can be employed in various embodiments.
- Y comprises Y m or Y n , m is between 1 and 5, n is between 75 and 85, p is between 85 and 95, and q is between 2 and 6. In several embodiments m is between 1 and 3, n is 79, p is 90, and q is 4.
- X is selected from the group consisting of insulin, proinsulin, preproinsulin, gluten, gliadin, myelin basic protein, myelin oligodendrocyte glycoprotein and proteolipid protein, Factor VIII, Factor IX, asparaginase, uricase and fragments of any of the preceding. In several embodiments, the antigen X is not a full length protein.
- the antigen is not full length gliadin, insulin, or proinsulin.
- the antigen X is not a fragment of a protein.
- m is not greater than 3
- n is not greater than 80
- p is not greater than 100
- q is not more than 5.
- Y is a linker moiety having a formula of:
- Y is a linker moiety having a formula of:
- Y is a linker moiety having a formula of:
- combinations of the linkers disclosed herein may be used, just as combinations of the liver targeting moieties can be employed.
- antigens to which tolerance may be desired. These may include, but are not limited to, exogenous antigens that result in an adverse immune response when a subject is exposed to the antigen.
- the adverse immune response could be a result of ingestion of the antigen, e.g., orally or nasally, or via some other mucosal route. These routes could be the case, for example, with food antigens.
- the antigen may be purposefully administered to a subject, for example, with the administration of a therapeutic composition to treat a disease or condition that the subject is affected by.
- the antigen may be produced by the subject, e.g., an autoimmune antigen.
- X comprises a foreign transplant antigen against which transplant recipients develop an unwanted immune response or a tolerogenic portion thereof.
- X comprises a foreign food, animal, plant or environmental antigen against which patients develop an unwanted immune response or a tolerogenic portion thereof.
- X comprises a foreign therapeutic agent against which patients develop an unwanted immune response or a tolerogenic portion thereof.
- X comprises a synthetic self-antigen against the endogenous version of which patients develop an unwanted immune response or a tolerogenic portion thereof.
- X is a food antigen.
- X is one or more of conarachin (Ara h 1), allergen II (Ara h 2), arachis agglutinin, conglutin (Ara h 6), a-lactalbumin (ALA), lactotransferrin, Pen a 1 allergen (Pen a 1 ), allergen Pen m 2 (Pen m 2), tropomyosin fast isoform, high molecular weight glutenin, low molecular weight glutenin, alpha- gliadin, gamma-gliadin, omega-gliadin, hordein, seclain, and avenin.
- X is selected from the group consisting of gluten, high molecular weight glutenin, low molecular weight glutenin, alpha- gliadin, gamma-gliadin, omega-gliadin, hordein, seclain, and avenin and fragments thereof.
- X is selected from the group consisting of gluten, high molecular weight glutenin, low molecular weight glutenin, alpha- gliadin, gamma-gliadin, and omega-gliadin and fragments thereof.
- X is gluten or fragment thereof.
- X is gliadin or fragment thereof.
- X is a therapeutic agent.
- X is selected from the group consisting of Factor VII, Factor IX, asparaginase, and uricase and fragments thereof.
- X is a therapeutic agent selected from the group consisting of Factor VII and Factor IX and fragments thereof.
- X is a therapeutic agent selected from the group consisting of Factor VIII or fragment thereof.
- the compound when X is a therapeutic agent, can be used in the treatment, prevention, reduction, or otherwise amelioration of an immune response developed against a therapeutic agent for hemophilia.
- mimotopes of any antigenic portion of the antigens above can be used in several embodiments.
- X comprises asparaginase or a fragment thereof. In several embodiments, X comprises uricase or a fragment thereof. In several such embodiments, the compound can be used in the treatment, prevention, reduction, or otherwise amelioration of an immune response developed against an anti-neoplastic agent. As discussed herein, mimotopes of any antigenic portion of the antigens above can be used in several embodiments.
- X is associated with an autoimmune disease.
- the associated autoimmune disease is one or more of Type I diabetes, multiple sclerosis, rheumatoid arthritis, vitiligo, uveitis, pemphis vulgaris and neuromyelitis optica.
- the autoimmune disease is Type I diabetes and X comprises insulin or a fragment thereof. In several embodiments, the autoimmune disease is Type I diabetes and X comprises proinsulin or a fragment thereof. In several embodiments, the autoimmune disease is Type I diabetes and X comprises preproinsulin or a fragment thereof.
- mimotopes of any antigenic portion of the antigens above can be used in several embodiments. In several embodiments, combinations of these antigens can be incorporated into the tolerogenic compound which may aid in reducing immune responses to self-antigens at multiple points along the insulin pathway.
- the autoimmune disease is multiple sclerosis and X comprises myelin basic protein or a fragment thereof. In several embodiments, the autoimmune disease is multiple sclerosis and X comprises myelin oligodendrocyte glycoprotein or a fragment thereof. In several embodiments, the autoimmune disease is multiple sclerosis and X comprises myelin proteolipid protein or a fragment thereof.
- mimotopes of any antigenic portion of the antigens above can be used in several embodiments. In several embodiments, combinations of these antigens can be incorporated into the tolerogenic compound which may aid in reducing immune responses to self- antigens at multiple points along the enzymatic pathways that control myelination or myelin repair.
- the autoimmune disease is rheumatoid arthritis and X is selected from the group consisting of fibrinogen, vimentin, collagen type II, alpha enolase and fragments thereof.
- the autoimmune disease is vitiligo and X is selected from the group consisting of Pmel17, tyrosinase and fragments thereof.
- the autoimmune disease is uveitis and X is selected from the group consisting of retinal arrestin and interphotoreceptor retinoid-binding protein (IRBP) and fragments thereof.
- IRBP interphotoreceptor retinoid-binding protein
- the autoimmune disease is pemphigus vulgaris and X is selected from the group consisting of desmoglein 3, 1 and 4, pemphaxin, desmocollins, plakoglobin, perplakin, desmoplakins, acetylcholine receptor and fragments thereof.
- the autoimmune disease is neuromyelitis optica and X is aquaporin-4 or a fragment thereof.
- mimotopes of any antigenic portion of the self-antigens above can be used in several embodiments.
- compositions comprising a compound disclosed above (or otherwise disclosed herein).
- the pharmaceutically acceptable composition consists of, or consists essentially of a compound wherein X is a food antigen, therapeutic agent, a self antigen, or fragment thereof, a linker Y, and a liver targeting moiety Z selected from glucose, galactose, glucosamine, galactosamine, N-acetylglucosamine, and N- acetylgalactosamine.
- the compound is administered prior to the subject being exposed to the antigen.
- the compound is administered after the subject has been exposed to the antigen.
- the administration comprises at least one intravenous administration of the compound (e.g., a bolus dose followed by a series of optional maintenance doses).
- compositions for inducing immune tolerance in a subject and methods and uses of the compositions for achieving the same.
- immune tolerance is desired because a subject develops an unwanted immune response to an antigen.
- the antigen may be one or more of a variety of antigens, for example a foreign antigen such as a food antigen that is ingested, or an antigenic portion of a therapeutic drug given to a subject.
- the antigen may be a self-antigen that the subject's immune system fails to recognize (or only recognizes as self to a limited degree) and therefore mounts an immune response against, leading to autoimmune disorders.
- composition comprising Formula 1 :
- X comprises a food antigen, a therapeutic agent, a self- antigen, a fragment of any of such antigens, or a mimotope of any of such antigens
- Y is of a linker moiety having the following formula:
- n is an integer from about 70 to 85
- present p is an integer from about 85 to 95
- present q is an integer from about 1 to 10
- present R 8 is -CH 2 - or -CH 2 -CH 2 -C(CH 3 )(CN)-
- present R 9 is a direct bond or -CH 2 -CH 2 — NH-C(O)-
- Z comprises a liver-targeting moiety comprising glucose or galactose.
- m is between 1 and 3
- n is 79
- p is 90
- q is 4.
- X is selected from the group consisting of insulin, proinsulin, preproinsulin, gluten, gliadin, myelin basic protein, myelin oligodendrocyte glycoprotein and proteolipid protein, Factor VIII, Factor IX, asparaginase, uricase and fragments of any of the preceding.
- the composition comprises, consists of, or consists essentially of the antigen X, the linker Y and the liver targeting moiety Z.
- X is selected from the group consisting of insulin, proinsulin, preproinsulin, gluten, gliadin, myelin basic protein, myelin oligodendrocyte glycoprotein and proteolipid protein, Factor VIII, Factor IX, asparaginase, uricase and fragments of any of the preceding
- Y is of a linker moiety having the following formula:
- n is an integer from about 70 to 85, where present p is an integer from about 85 to 95, where present q is an integer from about 1 to 10, where present R 8 is -CH 2 - or -CH 2 -CH 2 -C(CH 3 )(CN)-; and where present R 9 is a direct bond or -CH 2 -CH 2 — NH-C(O)-, and Z comprises a liver-targeting moiety comprising a sugar moiety.
- m is between 1 and 3
- n is 79
- p is 90
- q is 4.
- Z is selected from the group consisting of glucose, glucosamine, galactose, galactosamine, N-acetylgalactosamine and N-acetylglucosamine.
- 2,5-dioxopyrrolidin-1 -yl propyl carbonate-linkers and/or 2- (ethyldisulfanyl)ethyl ethylcarbamate-linkers can be used.
- composition comprising a compound of
- n is an integer from about 1 to 10;
- X comprises an antigen to which patients develop an unwanted immune response, wherein the antigen is a food antigen, a therapeutic agent, a self-antigen, or a fragment of any of such antigens;
- Y is of a linker moiety having a formula selected from the group consisting of:
- Formula YL wherein the left bracket "(" indicates a bond to X, where present the right ")” indicates a bond to Z, where present the bottom ")" indicates a bond to Z, where present n is an integer from about 1 to about 80, where present q is an integer from about 1 to about 4, where present p is an integer from about 1 to about 90, where present R 8 is -CH 2 - or -CH2-CH2-C(CH 3 )(CN)-, and Z comprises one or more liver- targeting moieties that specifically target liver cells expressing asialoglycoprotein receptors.
- m is 1 to 4
- Y is of a linker moiety having a formula of:
- ci- torm i na Y anc l ⁇ comprises a liver-targeting moiety comprising one or more of galactose, galactosamine, or N-acetyl galactosamine.
- n is resolved to an integer from 1 to 4
- Y is of a linker moiety having a
- Formula Ya and Z comprises a liver-targeting moiety comprising one or more of glucose, glucosamine, or N-acetyl glucosamine.
- compositions of Formula 1 (X-f— Y— Z] m ), where m is an integer from about 1 to 100, X comprises an antigen against which a patient develops an unwanted immune response, or a tolerogenic portion thereof or X comprises an antibody, antibody fragment or ligand that specifically binds a circulating protein or peptide or antibody, which circulating protein or peptide or antibody is causatively involved in transplant rejection, immune response against a therapeutic agent, autoimmune disease, hypersensitivity and/or allergy, Y comprises a linker moiety, and Z comprises a liver-targeting moiety.
- Z comprises galactose, galactosamine, N-acetylgalactosamine, glucose, glucosamine or N-acetylglucosamine.
- Y is selected from N-hydroxysuccinamidyl linkers, malaemide linkers, vinylsulfone linkers, pyridyl di-thiol-poly(ethylene glycol) linkers, pyridyl di-thiol linkers, n- nitrophenyl carbonate linkers, NHS-ester linkers, and nitrophenoxy poly(ethylene glycol)ester linkers.
- Y comprises an antibody, antibody fragment, peptide or other ligand that specifically binds X, a disulfanyl ethyl ester, a structure represented by one of Formulae Ya to Yp:
- Y has a portion represented by Formula Y'-CMP:
- the left bracket "(" indicates the bond between X and Y
- the right or bottom bracket and ")" indicates the bond between Y and Z
- n is an integer from about 1 to 100
- q is an integer from about 1 to 44
- R 8 is -CH 2 - or -CH 2 -CH 2 -C(CH 3 )(CN)-
- Y' represents the remaining portion of Y
- W represents a polymer of the same W 1 group, or W is a copolymer or a random copolymer of the same or different W 1 and W 2 groups, where:
- R is a direct bond, -CH 2 -CH 2 — NH-C(O)- or -CH 2 -CH2-(0-CH2-CH 2 )t-NH-C(0)-, t is an integer from 1 to 5; and R 1 ° is an aliphatic group, an alcohol or an aliphatic alcohol.
- m is 1 to 3
- Y is represented by Formula Ym, wherein R 8 is -CH 2 -CH 2 -C(CH 3 )(CN)-, and W is represented by a block copolymer of W 1 and W 2 where R 9 is -CH 2 -CH 2 -(0-CH 2 -CH 2 ) r NH-C(0)-, t is 1 , and R 1 ° is 2-hydroxypropyl; and Z comprises a liver- targeting moiety comprising one or more of galactose, galactosamine, N-acetylgalactosamine, glucose, glucosamine, N-acetylglucosamine. In several embodiments, Z is the ⁇ -anomer of the corresponding sugar.
- compositions for inducing tolerance to an antigen to which a subject develops an unwanted immune response, the compositions comprising a compound of Formula 1 (Formula 1 (X-f-Y— Z] m ), where m is an integer from about 1 to 10, X comprises an antigen to which patients develop an unwanted immune response, wherein the antigen is a food antigen, a therapeutic agent, a self-antigen, or a fragment of any of such antigens, Y is of a linker moiety having a formula selected from the group consisting of:
- n is an integer from about 1 to 100
- present p is an integer from about 2 to 150
- present q is an integer from about 1 to 44
- present R 8 is -CH 2 - or -CH2-CH2-C(CH 3 )(CN)-
- present R 9 is a direct bond or -CH 2 -CH 2 — NH-C(O)-
- Z comprises galactose, galactosamine, or N-acetylgalactosamine.
- m is 1 to 3
- Y is of a linker moiety having a formula of:
- Z comprises a liver-targeting moiety comprising one or more of galactose, galactosamine, or N-acetylgalactosamine.
- Z is the ⁇ -anomer of the selected moiety.
- X is a self-antigen and the unwanted immune response is an autoimmune response.
- X is myelin oligodendrocyte glycoprotein or myelin proteolipid protein.
- the unwanted immune response experienced by the subject is associated with multiple sclerosis.
- X is insulin, proinsulin, or preproinsulin and wherein the unwanted immune response is associated with diabetes mellitus. It shall be appreciated that being associated with multiple sclerosis, diabetes mellitus or other auto-immune disease need not necessarily require a formal diagnosis of such auto-immune condition, but rather can be associated with common symptoms or characteristics of a particular auto-immune disorder.
- an unwanted immune response can be raised against a therapeutic agent, such as a protein drug or drug derived from non-human and/or non- mammalian species.
- a therapeutic agent such as a protein drug or drug derived from non-human and/or non- mammalian species.
- X is a therapeutic agent, such as Factor VIII, Factor IX, or other hemostasis-inducing agent.
- the unwanted immune response is against the agent and the associated disease is hemophilia, which fails to improve (in the absence of the composition) because of the autoimmune response.
- the hemophilia can improve because the composition aids in inducing tolerance to the agent, reducing the response to agent, and allowing reduced symptoms of hemophilia.
- X is a therapeutic agent such as asparaginase and uricase.
- an unwanted immune response can result from administration of such agents, as they are derived from non-human sources.
- the ability of the compositions disclosed herein to induce tolerance to these agents allows these agents to continue to be used by a subject in need of therapy, while the side effects from an immune reaction are reduced, lessened, eliminated or otherwise ameliorated.
- X is a food antigen.
- Many food antigens are known to cause allergies upon ingestion, however, in several embodiments, X is selected from the group consisting of conarachin (Ara h 1 ), allergen II (Ara h 2), arachis agglutinin, conglutin (Ara h 6), a-lactalbumin (ALA), lactotransferrin, Pen a 1 allergen (Pen a 1), allergen Pen m 2 (Pen m 2), tropomyosin fast isoform, high molecular weight glutenin, low molecular weight glutenin, alpha- gliadin, gamma-gliadin, omega-gliadin, hordein, seclain, and avenin.
- treatment with the compositions disclosed herein where X is a food antigen allows the subject to have a significantly reduced immune response to the antigen, e.g., many peanut allergies are so severe that exposure to peanut dust or oil can cause anaphylaxis.
- treatment reduces and/or eliminates responses to such incidental exposure to the antigen.
- treatment allows the subject to ingest the food from which the antigen is derived with limited or no adverse immune response.
- administration of the composition to the subject results in a greater degree of proliferation of antigen-specific T cells as compared to proliferation of antigen-specific T cells resulting from administration of the antigen alone.
- the proliferation of antigen- specific T cells indicates that delivery of the antigen (via the composition) to the molecular processing machinery that processes antigens as self/non-self is enhanced versus administration of the antigen alone. In other words, in such embodiments the targeted delivery is effective.
- compositions disclosed herein results in a greater expression of exhaustion markers or markers of apoptosis on antigen-specific T cells as compared to expression of exhaustion markers or markers of apoptosis on antigen-specific T cells resulting from administration of the antigen alone. This result in indicative of specific reduction in activity of T cells directed against the antigen of interest and/or deletion of T cells directed against the antigen of interest.
- these molecular hallmarks of induction of tolerance are the precursor of the reduction or amelioration of immune response symptoms that the subject would have previously experienced when exposed to the antigen.
- Z comprises a liver-targeting moiety that is a carbohydrate.
- the carbohydrate is a short-chain carbohydrate.
- Z is a sugar.
- Z is galactose, galactosamine, N-acetylgalactosamine, glucose, glucosamine, or N-acetylglucosamine.
- the induction of immune tolerance is greater when a glucose, glucosamine, or N-acetylglucosamine is used for Z.
- enhancements in induction of immune tolerance can be achieved when the liver targeting moiety is a sugar and the sugar is in the ⁇ -anomer configuration.
- Z is galactose, galactosamine, N-acetylgalactosamine, glucose, glucosamine, or N-acetylglucosamine and conjugated at its C1 , C2 or C6 to Y.
- compositions can be via a variety of methods, including, but not limited to intravenous, intramuscular, oral, transdermal, or other infusion route. Administration can be daily, weekly, multiple times per day, or on an as needed basis (e.g., prior to an anticipated exposure).
- compositions disclosed herein for the treatment of unwanted immune responses after exposure to an antigen.
- such use can be for prophylactic effects and/or for reducing symptoms from prior exposure to antigens (or prior adverse immune effects, such as those in the auto-immune setting).
- compositions according to Formula 1 for the treatment of unwanted side effects due to exposure to a therapeutic antigen, exposure to a food antigen, or an adverse effect from an immune response against a self-antigen.
- the compositions disclosed herein are suitable for administration to a subject in conjunction with such use, for example by oral, IV, IM, or other suitable route. Uses of the compositions disclosed herein, in several embodiments, unexpectedly result in the reduction, elimination or amelioration of adverse immune responses to antigens of interest.
- compositions and methods of using them are provided herein.
- a pharmaceutically acceptable composition for inducing tolerance to a therapeutic protein in a subject having an deficiency in production of a functional analogous native protein comprising a compound of Formula 1 (X-f— Y— Z] m ), where m is an integer from about 1 to 10, X comprises an antigenic protein or protein fragment, Y is of a linker moiety having a formula selected from the group consisting of Formula Ya, Formula Yc, Formula Ym, Formula Yn, wherein, the left bracket "(" indicates a bond to X, the right or bottom bracket and ")" indicates the bond between Y and Z, n is an integer from about 1 to 100, where present p is an integer from about 2 to 150, where present q is an integer from about 1 to 44, where present R 8 is -CH 2 - or -CH 2 -CH 2 -C(CH 3 )(CN)-, where present
- Y is of a linker moiety having a formula of: wherein CH 2 -CH 2 — NH-C(O)-, and Z comprises a liver-targeting moiety comprising one or more of glucose, glucosamine, N- acetylglucosamine, galactose, galactosamine, or N-acetylgalactosamine.
- the galactose, galactosamine, or N-acetylgalactosamine are the ⁇ -anomers.
- combinations of galactose, galactosamine, N-acetylgalactosamine, glucose, glucosamine, or N- acetylglucosamine are used.
- a pharmaceutically acceptable composition for inducing tolerance to a therapeutic protein in a subject having an deficiency in production of a functional analogous native protein comprising a compound of Formula 1 (X- ⁇ -Y— Z] m ), where m is an integer from about 1 to 10, X comprises a antigenic protein or protein fragment, Y is of a linker moiety having a formula selected from the group consisting of Formula Ya, Formula Yc, Formula Ym, or Formula Ym, wherein the left bracket "(" indicates a bond to X, where present the right ")" indicates a bond to Z, where present the bottom ")" indicates a bond to Z, where present n is an integer from about 1 to about 80, where present q is an integer from about 1 to about 4, where present p is an integer from about 1 to about 90, where present R 8 is -CH 2 - or -CH 2 -CH 2 -C(CH 3 )(CN)-, and where present W represents
- R 10 is an aliphatic group, an alcohol or an aliphatic alcohol
- Z comprises glucose, glucosamine, N-acetylglucosamine, galactose, galactosamine, or N-acetylgalactosamine.
- the galactose, galactosamine, or N-acetylgalactosamine are the ⁇ -anomers.
- combinations of galactose, galactosamine, N-acetylgalactosamine, glucose, glucosamine, or N-acetylglucosamine are used.
- m is 1 to 3
- Y is represented by Formula Ym, wherein R 8 is -CH 2 -CH 2 -C(CH 3 )(CN)-, and W is represented by a block copolymer of W 1 and W 2 where R 9 is -CH2-CH 2 -(0-CH 2 -CH 2 )t-NH-C(0)-, t is 1 , and R 10 is 2-hydroxypropyl; and Z comprises a liver- targeting moiety comprising one or more of glucose, glucosamine, N-acetylglucosamine, galactose, galactosamine, or N-acetylgalactosamine.
- the galactose, galactosamine, or N- acetylgalactosamine are the ⁇ -anomers. In several embodiments, combinations of galactose, galactosamine, N-acetylgalactosamine, glucose, glucosamine, or N-acetylglucosamine are used.
- X comprises an antigenic region of myelin basic protein, myelin oligodendrocyte glycoprotein, or myelin proteolipid protein. In additional embodiments, X comprises an antigenic region of Factor VIII, Factor IX, insulin, uricase, PAL, or asparaginase.
- X comprises a foreign antigen such as conarachin (Ara h 1 ), allergen II (Ara h 2), arachis agglutinin, conglutin (Ara h 6), a-lactalbumin (ALA), lactotransferrin, Pen a 1 allergen (Pen a 1 ), allergen Pen m 2 (Pen m 2), tropomyosin fast isoform, high molecular weight glutenin, low molecular weight glutenin, alpha- gliadin, gamma-gliadin, omega-gliadin, hordein, seclain, and avenin.
- a foreign antigen such as conarachin (Ara h 1 ), allergen II (Ara h 2), arachis agglutinin, conglutin (Ara h 6), a-lactalbumin (ALA), lactotransferrin, Pen a 1 allergen (Pen a 1 ), allergen Pen
- compositions comprising a compound of Formula 1 (X-[- Y— Z]m), where m is an integer from about 1 to 100, X comprises an antigen against which a patient develops an unwanted immune response, or a tolerogenic portion thereof, or X comprises an antibody, antibody fragment or ligand that specifically binds a circulating protein or peptide or antibody, which circulating protein or peptide or antibody is causatively involved in transplant rejection, immune response against a therapeutic agent, autoimmune disease, hypersensitivity and/or allergy, Y comprises a linker moiety, and Z comprises a liver-targeting moiety.
- X comprises an antigen against which a patient develops an unwanted immune response, or a tolerogenic portion thereof
- X comprises an antibody, antibody fragment or ligand that specifically binds a circulating protein or peptide or antibody, which circulating protein or peptide or antibody is causatively involved in transplant rejection, immune response against a therapeutic agent, autoimmune disease, hypersensitivity and/or allergy
- Y comprises
- Z galactose, galactosamine, N-acetylgalactosamine, glucose, glucosamine or N-acetylglucosamine are examples of galactose, galactosamine,
- N-acetylgalactosamine, glucose, glucosamine or N-acetylglucosamine may also be used, in several embodiments. Further, in several embodiments, the galactose, galactosamine, N-acetylgalactosamine, glucose, glucosamine or N-acetylglucosamine are optionally the ⁇ anomer. In several embodiments, Z is conjugated at its C1 , C2 or C6 to Y.
- Y is selected from N-hydroxysuccinamidyl linkers, malaemide linkers, vinylsulfone linkers, pyridyl di-thiol-poly(ethylene glycol) linkers, pyridyl di-thiol linkers, n- nitrophenyl carbonate linkers, NHS-ester linkers, and nitrophenoxy poly(ethylene glycol)ester linkers.
- Y comprises an antibody, antibody fragment, peptide or other ligand that specifically binds X, a disulfanyl ethyl ester, a structure represented by one of Formulae Ya to Yp, or Y has a portion represented by Formula Y'-CMP:
- Formula Y'-CMP where the left bracket “(" indicates the bond between X and Y, the right or bottom bracket and ")" indicates the bond between Y and Z, n is an integer from about 1 to 100, q is an integer from about 1 to 44, R 8 is -CH 2 - or -CH 2 -CH 2 -C(CH 3 )(CN)-, Y' represents the remaining portion of Y, and W represents a polymer of the same W 1 group, or W is a copolymer or a random copolymer of the same or different W 1 and W 2 groups, where:
- R 9 is a direct bond, -CH 2 -CH 2 — NH-C(O)- or -CH 2 -CH 2 -(0-CH2-CH 2 )t-NH-C(0)-, t is an integer from 1 to 5; and R 10 is an aliphatic group, an alcohol or an aliphatic alcohol.
- n is about 40 to 80, p is about 10 to 100, q is about 3 to 20, R 8 is -CH 2 -CH 2 -C(CH3)(CN)-, when R9 is -CH2-CH2— NH-C(O)-, Z is glucose, galactose, N- acetylgalactosamine or N-acetylglucosamine conjugated at its C1 , and when W is a copolymer, R10 is 2-hydroxypropyl.
- Y comprises Formula Ya, Formula Yb, Formula Yc, Formula Yf, Formula Yg, Formula Yh, Formula Yi, Formula Yk, Formula Ym or Formula Yn.
- Y comprises Formula Ya, Formula Yb, Formula Yc, Formula Ym or Formula Yn.
- Y comprises Formula Ya, Formula Yb, Formula Yc, Formula Ym or Formula Yn.
- X comprises a foreign transplant antigen against which transplant recipients develop an unwanted immune response, a foreign food, animal, plant or environmental antigen against which patients develop an unwanted immune response, a foreign therapeutic agent against which patients develop an unwanted immune response, or a synthetic self-antigen against the endogenous version of which patients develop an unwanted immune response, or a tolerogenic portion thereof.
- a foreign transplant antigen against which transplant recipients develop an unwanted immune response a foreign food, animal, plant or environmental antigen against which patients develop an unwanted immune response, a foreign therapeutic agent against which patients develop an unwanted immune response, or a synthetic self-antigen against the endogenous version of which patients develop an unwanted immune response, or a tolerogenic portion thereof.
- Also provided for herein is methods of treatment for an unwanted immune response against an antigen by administering to a mammal in need of such treatment an effective amount of a composition comprising a compound of Formula 1 (X-[- Y— Z]m), where m is an integer from about 1 to 100, X comprises an antigen against which a patient develops an unwanted immune response, or a tolerogenic portion thereof or X comprises an antibody, antibody fragment or ligand that specifically binds a circulating protein or peptide or antibody, which circulating protein or peptide or antibody is causatively involved in transplant rejection, immune response against a therapeutic agent, autoimmune disease, hypersensitivity and/or allergy, Y comprises a linker moiety, and Z comprises a glucosylated liver-targeting moiety.
- X comprises an antigen against which a patient develops an unwanted immune response, or a tolerogenic portion thereof
- Y comprises, an antibody, antibody fragment, peptide or other ligand that specifically binds X, a disulfanyl ethyl ester, a structure represented by one of Formulae Ya to Yp or Y has a portion represented by Formula Y'-CMP where, the left bracket "(" indicates the bond between X and Y, the right or bottom bracket and ")" indicates the bond between Y and Z, n is an integer from about 1 to 100, q is an integer from about 1 to 44, R 8 is - CH 2 - or -CH 2 -CH2-C(CH 3 )(CN)-, Y' represents the remaining portion of Y, and W represents a polymer of the same W 1 group, or W is a copolymer or a random copolymer of the same or different W 1 and W 2 groups, where:
- X comprises the antibody, antibody fragment or ligand, and the composition is administered for clearance of a circulating protein or peptide or antibody that specifically binds to X, which circulating protein or peptide or antibody is causatively involved in transplant rejection, immune response against a therapeutic agent, autoimmune disease, hypersensitivity and/or allergy.
- X comprises the antibody, antibody fragment or ligand, and the composition is administered in an amount effective to reduce a concentration of the antibodies that are causatively involved in transplant rejection, immune response against a therapeutic agent, autoimmune disease, hypersensitivity and/or allergy in blood of the patient by at least 50% w/w, as measured at a time between about 12 to about 48 hours after the administration.
- compositions are administered for tolerization of the patient with respect to antigen moiety X.
- X comprises a foreign transplant antigen against which transplant recipients develop an unwanted immune response, a foreign food, animal, plant or environmental antigen against which patients develop an unwanted immune response, a foreign therapeutic agent against which patients develop an unwanted immune response, or a synthetic self-antigen against the endogenous version of which patients develop an unwanted immune response, or a tolerogenic portion thereof.
- compositions comprising a compound of Formula 1 :
- n is an integer from about 1 to 100;
- X comprises an antigen against which a patient develops an unwanted immune response, or a tolerogenic portion thereof; or X comprises an antibody, antibody fragment or ligand that specifically binds a circulating protein or peptide or antibody, which circulating protein or peptide or antibody is causatively involved in transplant rejection, immune response against a therapeutic agent, autoimmune disease, hypersensitivity and/or allergy;
- Y comprises a linker moiety
- Z comprises a liver-targeting moiety.
- Z can also comprise galactose, galactosamine, N-acetylgalactosamine, glucose, glucosamine or N-acetylglucosamine, for example, conjugated at its C1 , C2 or C6 to Y.
- N- acetylglucosamine and glucose bind to different lectin receptors as do N-acetylgalactosamine and galactose.
- the experimental data indicate that the selection of Z as N-acetylglucosamine leads to elevated levels of regulatory T cell responses compared to those achieved with N-acetylgalactosamine. In several embodiments, this results in unexpectedly enhanced induction of immune tolerance and/or clearance of antigens from the blood of a subject.
- Y can be selected from N-hydroxysuccinamidyl linkers, malaemide linkers, vinylsulfone linkers, pyridyl di-thiol-poly(ethylene glycol) linkers, pyridyl di-thiol linkers, n-nitrophenyl carbonate linkers, NHS-ester linkers, and nitrophenoxy poly(ethylene glycol)ester linkers.
- Y can also comprise: an antibody, antibody fragment, peptide or other ligand that specifically binds X; a disulfanyl ethyl ester; a structure represented by one of Formulae Ya to Yp:
- Y has a portion represented by Formula Y'-CMP:
- n is an integer from about 1 to 100;
- q is an integer from about 1 to 44;
- R 8 is -CH 2 - or -CH 2 -CH 2 -C(CH 3 )(CN)-;
- Y' represents the remaining portion of Y (e.g., HS-PEG).
- W represents a polymer of the same W 1 group, or W is a copolymer (preferably a random copolymer) of the same or different W 1 and W 2 groups, where:
- p is an integer from 2 to about 150;
- R 9 is a direct bond, -CH 2 -CH 2 — NH-C(O)- (i.e., an ethylacetamido group or "EtAcN”) or -CH 2 -CH 2 -(0-CH 2 -CH 2 ) t -NH-C(0)- (i.e., a pegylated ethylacetamido group or "Et- PEGt-AcN”)
- t is an integer from 1 to 5, (particularly 1 to 3, and more particularly 1 or 2);
- R 10 is an aliphatic group, an alcohol or an aliphatic alcohol.
- R 10 is a C f alkyl or C f alkylOH g where f is independently an integer between 0 and 10 and g is independently an integer between 0 and 10.
- R 10 is 2- hydroxypropyl.
- linkers according to Ym yield unexpectedly effective tolerance endpoints.
- linkers according to formula Yn yield unexpectedly effective tolerance endpoints.
- formulations of Fl m'-OVA-m ⁇ -nyg-pgo-q ⁇ CMP-poly-iEtPEGiAcN-I NAcGLUao- ran-HPMA 60 achieve particularly effective tolerance-associated endpoints.
- combinations of these linkers lead to synergistic results and still further unexpected increases in immune tolerance induction.
- n is about 40 to 80
- p is about 10 to 100
- q is about 3 to 20
- R 8 is -CH 2 -CH 2 -C(CH 3 )(CN)-
- R 9 is -CH 2 -CH 2 — NH-C(O)-
- Z is galactose or N- acetylgalactosamine conjugated at its C1.
- Y comprises Formula Ya, Formula Yb, Formula Yh, Formula Yi, Formula Yk, Formula Ym or Formula Yn, particularly Formula Ya, Formula Yb, Formula Ym or Formula Yn.
- X can further comprise: a foreign transplant antigen against which transplant recipients develop an unwanted immune response; a foreign food, animal, plant or environmental antigen against which patients develop an unwanted immune response; a foreign therapeutic agent against which patients develop an unwanted immune response; or a synthetic self-antigen against the endogenous version of which patients develop an unwanted immune response, or a tolerogenic portion thereof.
- the disclosure also pertains to a method of treatment for an unwanted immune response against an antigen by administering to a mammal in need of such treatment an effective amount of a composition comprising a compound of Formula 1 as disclosed herein.
- the composition can be administered for clearance of a circulating protein or peptide or antibody that specifically binds to antigen moiety X, which circulating protein or peptide or antibody is causatively involved in transplant rejection, immune response against a therapeutic agent, autoimmune disease, hypersensitivity and/or allergy.
- the composition can be administered in an amount effective to reduce a concentration of the antibodies that are causatively involved in transplant rejection, immune response against a therapeutic agent, autoimmune disease, hypersensitivity and/or allergy in blood of the patient by at least 50% w/w, as measured at a time between about 12 to about 48 hours after the administration.
- the composition can administered for tolerization of a patient with respect to antigen moiety X.
- Figs. 1A-1 D are a series of graphs showing differential cellular uptake of galactose conjugates.
- Figure 1A depicts that F1 aA-PE-m 4 -n 80 (Gal-PE) preferentially targets PE to sinusoidal endothelial cells (LSECs) of the liver.
- Figure 1 B depicts that F1 aA-PE-m 4 -n 80 (Gal-PE) preferentially targets PE to Kupffer cells (KC) of the liver.
- Figure 1 C depicts that F1 aA-PE-m 4 -n 80 (Gal-PE) preferentially targets PE to hepatocytes.
- Figure 1 D depicts that F1 aA-PE-m 4 -n 80 (Gal-PE) preferentially targets PE to other antigen presenting cells (APCs) of the liver.
- * P ⁇ 0.05.
- Fig. 2 is a graph showing proliferation of OT-I CD8+ T cells in mice treated with F1 aA-OVA- m 4 -n 80 (Gal-OVA), OVA or saline (i.e. naive), with greatest proliferation seen in the Gal-OVA treated group.
- FIGs. 3A-3B are a series of graphs depicting data related to marker expression on T cells.
- Figure 3A shows the percentage of OT-I CD8 + T cells expressing PD-1 ("PD1 +") in generations of proliferating T cells treated with saline, OVA or F1 aA-OVA-m 4 -n 80 (GAL-OVA), with greatest level of PD- 1 in the gal-OVA-treated group.
- Figure 3B shows the percentage of OT-I CD8 + T cells expressing phosphatidylserine (stained as "Annexin V+”) in generations of proliferating T cells treated with saline, OVA or F1 aA-OVA-m 4 -n 80 (GAL-OVA), with greatest level of Annexin-V+ cells in the gal-OVA-treated group.
- Fig. 4 is a graph showing that galactose conjugation [F1 aA-OVA-m 4 -n 80 (Gal-OVA)] decreases the immunogenicity of OVA as determined by OVA-specific antibody titers (shown in Ab titers log "1 ).
- FIG. 5 shows that administration of F1 aA-OVA-m 4 -n 80 (Gal-OVA) in repeated doses over time is able to deplete OVA-specific antibodies from the serum of mice.
- Figure 6A shows the immune response in mice challenged with OVA and LPS.
- Figure 6B shows the immune response in mice treated with OVA, while Figure 6C shows the immune response in naive mice.
- Figures 6D and 6E show that F1 aA-OVA-m 4 -n 80 (mGal-OVA; 6D) and F1 b-OVA-m 1 -n 4 4-p 3 4 (pGal-OVA; 6E) are able to mitigate the OVA-specific immune response in draining lymph nodes after intradermal challenge with OVA and the adjuvant LPS.
- Fig 6F is from a parent application and does not form a part of the present disclosure.
- Figs. 7A-7B shows the characterization of F1 aA-OVA-m 4 -n 80 and F1 b-OVA-m 1 -n 44 -p 34 .
- Fig. 7A shows size-exclusion HPLC traces of F1 aA-OVA-m 4 -n 80 (open triangles), F1 b-OVA-m 1 -n 44 -p 34 (filled circles) and unconjugated OVA (solid line). Shift to the left represents an increase in molecular weight.
- Fig. 7A-7B shows the characterization of F1 aA-OVA-m 4 -n 80 and F1 b-OVA-m 1 -n 44 -p 34 .
- Fig. 7A shows size-exclusion HPLC traces of F1 aA-OVA-m 4 -n 80 (open triangles), F1 b-OVA-m 1 -n 44 -p 34 (filled circles) and unconjugated OVA (solid
- Figs. 8A-8B depict data related to the reduction in antigen-specific immune response after administration of Fl m'-OVA-m ⁇ a-nyg-pgo-q ⁇ CMP-poly-iEtPEGiAcN-I NAcGLUao-ran-HPMAeo [labeled OVA-p(Glu-HPMA) and shown as filled circles] or Fl m'-OVA-m ⁇ -nyg-pgo-q ⁇ CMP-poly-iEtPEGiAcN- 1 NAcGAL 3 o-ran-HPMA6o [labeled OVA-p(Gal-HPMA) and shown as filled diamonds].
- FIG. 8A depicts flow cytometric detection of OTI CD8+ T-cell populations (CD3e + /CD8a + /CD45.2 + ) quantified from the draining lymph nodes (inguinal and popliteal) 4 days following antigen challenge in CD45.1 + mice.
- Significant reductions in OT-I CD8+ T-cells were detected following administration of OVA-p(Gal-HPMA) and OVA-p(Glu-HPMA).
- Fig. 8B depicts flow cytometric detection of OTII CD4+ T-cell populations (CD3e + /CD4 + /CD45.2 + ) quantified from the draining lymph nodes (inguinal and popliteal) 4 d following antigen challenge in CD45.1 + mice.
- Figs. 9A-9B depict data related to the increase in antigen-specific regulatory T-cells in the lymph nodes and spleen of mice after antigen challenge.
- Fig. 9A depicts flow cytometric detection of an Fl m'-OVA-mLa-nyg-pgo-q ⁇ CMP-poly-iEtPEdAcN-I NAcGLUso-ran-HPMAeo [labeled OVA-p(Glu-HPMA) and shown as filled circles] and Fl m'-OVA-m ⁇ -nyg-pgo-q ⁇ CMP-poly-iEtPEGiAcN-I NAcGALso-ran- HPMA 60 [labeled OVA-p(Gal-HPMA) and shown as filled diamonds]-induced increase in OTII T-regulator cells (CD3e + CD4+ CD45.2+ CD25+ FoxP3+) collected from the lymph nodes 4 d following antigen challenge in CD45.1 + mice.
- Fig. 10 depicts flow cytometry data related to a decrease in the percentage of antigen-specific effector cells (IFNy+ OTI CD8+ T-cells (CD3e + CD8a+ CD45.2+ IFNy+) 4 d following antigen challenge in CD45.1 + mice.
- IFNy+ OTI CD8+ T-cells CD3e + CD8a+ CD45.2+ IFNy+
- Figs. 1 1A-1 1 B depict data related to T cell deletion and regulation in an OTII adoptive transfer model, in which OTII cells (CD4 + T cells from a CD45.2 + mouse) are adoptively transferred into a CD45.1 + recipient, which is treated with Fl m'-OVA-m ⁇ -nyg-pgo-q ⁇ CMP-poly-iEtPEGiAcN- I NAcGALso-ran-HPMAgo ["OVA-p(Gal-HPMA)”] or F1 m'-OVA-m ⁇ -nyg-pgo-q ⁇ CMP-poly- EtPEGiAcN- I NAcGLUso-ran-HPMAgo ["OVA-p(Glu-HPMA)”], or OVA not linked to a polymer ["OVA”] to induce T regulatory responses and prevent subsequent responses to vaccine-mediated antigen challenge.
- OTII cells CD4 + T cells from a CD45.2 + mouse
- pGal-OVA and pGlu-OVA were each administered in other groups at the same dosings of 2.5 pg at day 1 , 2.5 pg at day 4, and 16 pg at day 7 or 7 pg at day 1 , 7 pg at day 4, and 7 pg at day 7, all doses being on an OVA equivalent dose basis.
- saline was administered on the same days.
- the recipient mice were then challenged with OVA (10 pg) adjuvanted with lipopolysaccharide (50 ng) by intradermal injection. Characterization of the draining lymph nodes was done on day 19, to allow determination as to whether or not deletion actually took place and whether regulatory T cells were induced from the adoptively transferred cells.
- Fig. 1 1 A shows the number of OTII cells present after challenge
- Fig. 1 1 B shows the frequency of FoxP3 + CD25 + cells (markers of T regulatory cells). * and # indicate p ⁇ 0.05, ** and ## indicate p ⁇ 0.01 , and ### indicates P ⁇ 0.001.
- Figs. 12A-12B depicts data related to T cell deletion and regulation in an OTI adoptive transfer model, in which OTI cells (CD8 + T cells from a CD45.2 + mouse) are adoptively transferred into a CD45.1 + recipient, which is treated with Fl m'-OVA-m ⁇ -nyg-pgo-q ⁇ CMP-poly- EtPEG ⁇ cN-I NAcGALso- ran-HPMA 60 ["OVA-p(Gal-HPMA)"] or F1 m'-OVA-m ⁇ -nyg-pgo-q ⁇ CMP-poly- EtPEG ⁇ cN-l NAcGLU 30 - ran-HPMA 60 [OVA-p(Glu-HPMA)"], or OVA not linked to a polymer ["OVA”] to induce T regulatory responses and prevent subsequent responses to vaccine-mediated antigen challenge.
- pGal-OVA and pGlu-OVA were each administered in other groups at the same dosings of 2.5 pg at day 1 , 2.5 pg at day 4, and 16 pg at day 7 or 7 pg at day 1 , 7 pg at day 4, and 7 pg at day 7, all doses being on an OVA equivalent dose basis.
- saline was administered on the same days.
- the recipient mice were then challenged with OVA (10 pg) adjuvanted with lipopolysaccharide (50 ng) by intradermal injection.
- Fig. 12A shows the number of OTI cells present after challenge
- Fig. 12B shows the frequency of IFNy- expressing cells (lack thereof indicating anergy). * and # indicate p ⁇ 0.05, ** and ## indicate p ⁇ 0.01 ).
- FIG. 13 depicts data related to blood glucose levels. Mice were treated with F1 m , -P31 -m 1 ⁇ -n 7 9-P9o-q4-CMP-poly-(EtPEGiAcN-1 NAcGLU3o-ran-HPMA 60 [labeled P31 -p(Glu-HPMA)], Fl m'-PSI -m ⁇ a-nyg-pgo-q -CMP-poly-iEtPEG ⁇ cN-I NAcGALao-ran-HPMAeo [labeled P31-p(Gal-HPMA) conjugates (or saline).
- Fig. 14 depicts data related to the generation of spontaneous diabetes in non-obese diabetic (NOD) mice.
- Mice treated with Fl c'-lnsulin-B-m n ⁇ pgo-CMP-poly- EtPEGiAcN-I NAcGLUso-ran- HPMA 60 are shown as filled squares.
- Mice treated with Fl c'-lnsulin-B-nvn ⁇ pgo-CMP-poly-iEtPEG ⁇ cN- 1 NAcGALso-ran-HPMAeo are shown as filled triangles.
- Mice treated with saline are shown as filled diamonds.
- Treating animals with the compounds of Formula 1 reduced the incidences of diabetes onset in NOD mice as compared to animals treated with saline.
- Figs. 15A-15B depicts data related to biodistribution of the model antigen OVA tethered to the synthetic glycopolymers, showing uptake in the liver while limiting uptake in the spleen.
- A Fluorescent signal of perfused livers taken from animals treated with OVA (1 ) or OVA conjugated to various glycopolymers (2-5).
- B Fluorescent images of spleens taken from animals treated with OVA (1 ) or OVA conjugated to various glycopolymers (2-5).
- Formulations are as follows: 1. OVA, 2. OVA- p(Ga ⁇ -HPMA), 3. OVA-p(Gal-HPMA), 4. OVA-p(Glu -HPMA), 5. OVA-p(Glu-HPMA).
- FIGS. 16A-16F depict data related to experiments comparing linker moieties.
- OVA-p(Gal- HPMA), OVA-p(Glu-HPMA), OVA-p(Gai -HPMA), and OVA-p(Glu -HPMA) conjugates were synthesized and tested for their ability to induce antigen-specific T cell anergy and eliminate the T cell population responsible for long term memory.
- Fig. 16A shows a schematic of the treatment regimen for 7-day experiment.
- Fig. 16B depicts the percentage of proliferating OTI splenic T cells as assayed by CSFE dilution.
- FIG. 16C depicts the percentage of Annexin V+ OTI T cells in the spleens of animals treated with OVA-glycopolymer conjugates or free OVA.
- Fig. 16D depicts the percentage of PD-1 + splenic OTI cells.
- Fig. 16E depicts the percentage of T memory cells in the OTI population, where T memory cells was defined as CD62L+ and CD44+.
- Fig. 16 F depicts the percentage of OTI cells expressing CD127.
- Fig. 17 depicts data related to development of symptoms of diabetes in naive, control, and experimental groups.
- Fig. 18 depicts the various treatment groups and the experimental timeline used in an experiment related to evaluation of induction of long-lasting tolerance in transferred T cells.
- Figures 19A-19B depict data related to T cell composition in the lymph node.
- Figure 19A depicts the remaining OTI cells after antigen challenge (as a percentage of total CD8 + cells) in the various treatment groups.
- Figure 19B depicts the remaining OTI I cells after antigen challenge (as a percentage of total CD4 + cells) in the various treatment groups.
- Fig. 20 depicts the various treatment groups and the experimental timeline used in an experiment related to evaluation of induction of long-lasting tolerance in endogenous T cells.
- Figures 21 A-21 B depict data related to T cell composition in the lymph node.
- Figure 21 A depicts the remaining OTI cells after antigen challenge (as a percentage of total CD8 + cells) in the various treatment groups.
- Figure 21 B depicts the remaining OTII cells after antigen challenge (as a percentage of total CD4 + cells) in the various treatment groups.
- Fig. 22 depicts the experimental design used to evaluate the ability of compositions as disclosed herein to prophylactically reduce antibody response.
- Fig. 23 depicts experimental data related to the amount of anti-asparaginase antibodies from mice in the various treatment groups.
- Figures 24A-24B depict the experimental design and composition used in evaluating tolerance to myelin oligodendrocyte glycoprotein (MOG).
- Fig. 24A shows the experimental protocol used in immunizing donor mice and treating recipient mice.
- Fig. 24B shows one example of a tolerogenic composition in accordance with several embodiments disclosed herein.
- Figures 25A-25B depict experimental data related to induction of tolerance against MOG using a first concentration of the tolerogenic composition.
- Fig. 25A depicts data related to delay of disease onset in the various treatment groups.
- Fig. 25B depicts data related to reduction of weight loss in the various treatment groups.
- Figures 26A-26B depict experimental data related to induction of tolerance against MOG using an additional concentration of the tolerogenic composition.
- Fig. 26A depicts data related to delay of disease onset in the various treatment groups.
- Fig. 26B depicts data related to reduction of weight loss in the various treatment groups.
- FIG.27A depicts targeting of OVA via various conjugates to LSECs in the liver.
- Fig.27B depicts targeting of OVA via various conjugates to Kupffer cells in the liver.
- Fig.27C depicts targeting of OVA via various conjugates to CD11 c+ cells in the liver.
- Fig.27D depicts targeting of OVA via various conjugates to hepatocytes in the liver.
- Fig.27E depicts targeting of OVA via various conjugates to stellate cells in the liver.
- ASGPRs asialoglycoprotein receptors
- LSECs liver sinusoidal endothelial cells
- Other galactose/galactosamine/N-acetylgalactosamine receptors can be found in various forms on multiple cell types [e.g., dendritic cells, hepatocytes, LSECs, and Kupffer cells].
- Dendritic cells are considered "professional antigen presenting cells," because their primary function is to present antigens to the immune system for generating immune responses. Some cells within the liver are known to be able to present antigens, but the liver is more known to be involved in tolerogenesis. The liver is understood to be a tolerogenic organ.
- glycosylation i.e., the presence of significant numbers of glycosylated proteins.
- glycophorins e.g., glycophorin A
- Glycophorins are proteins with many covalently attached sugar chains, the terminus of which is sialic acid. As an erythrocyte ages and becomes ripe for clearance, the terminal sialic acid of its glycophorins tends to be lost, leaving N-acetylgalactosamine at the free end.
- N-acetylgalactosamine is a ligand selectively received by the ASGPR associated with hepatic cells, leading to binding of N-acetylgalactosamine-containing substances by hepatic cells and their subsequent uptake and processing in the liver.
- the present disclosure provides, in several embodiments, certain therapeutic compositions that are targeted for delivery to (and for uptake by) the liver, particularly hepatocytes, LSECs, Kupffer cells and/or stellate cells, more particularly hepatocytes and/or LSECs, and even more particularly to specifically bind ASGPR.
- Liver-targeting facilitates two mechanisms of treatment: tolerization and clearance.
- Tolerization takes advantage of the liver's role in clearing apoptotic cells and processing their proteins to be recognized by the immune system as "self," as well as the liver's role in sampling peripheral proteins for immune tolerance. Clearance takes advantage of the liver's role in blood purification by rapidly removing and breaking down toxins, polypeptides and the like.
- compositions to the liver is accomplished by a galactosylating moiety (e.g., galactose, galactosamine and N-acetylgalactosamine, particularly conjugated at C1 , C2 or C6, though some embodiments involved conjugation at other or any carbon in the molecule), by a glucosylating moiety (e.g., glucose, glucosamine and N-acetylglucosamine, particularly conjugated at C1 , C2 or C6, though some embodiments involved conjugation at other or any carbon in the molecule), or by de-sialylating a polypeptide for which such liver-targeting is desired.
- a galactosylating moiety e.g., galactose, galactosamine and N-acetylgalactosamine, particularly conjugated at C1 , C2 or C6, though some embodiments involved conjugation at other or any carbon in the molecule
- a glucosylating moiety e
- the galactosylating or glucosylating moiety can be chemically conjugated or recombinantly fused to an antigen, whereas desialylation exposes a galactose- like moiety on an antigen polypeptide.
- the antigen can be endogenous (a self-antigen) or exogenous (a foreign antigen), including but not limited to: a foreign transplant antigen against which transplant recipients develop an unwanted immune response (e.g., transplant rejection), a foreign food, animal, plant or environmental antigen to which patients develop an unwanted immune (e.g., allergic or hypersensitivity) response, a therapeutic agent to which patients develop an unwanted immune response (e.g., hypersensitivity and/or reduced therapeutic activity), a self-antigen to which patients develop an unwanted immune response (e.g., autoimmune disease), or a tolerogenic portion (e.g., a fragment or an epitope) thereof; these compositions are useful for inducing tolerization to the antigen.
- a foreign transplant antigen against which transplant recipients develop an unwanted immune response e.g., transplant rejection
- a foreign food, animal, plant or environmental antigen to which patients develop an unwanted immune (e.g., allergic or hypersensitivity) response e.g., a therapeutic agent to which patients develop an unwanted immune
- the galactosylating or other liver-targeting moiety can be conjugated to an antibody, antibody fragment or ligand that specifically binds a circulating protein or peptide or antibody, which circulating protein or peptide or antibody is causatively involved in transplant rejection, immune response against a therapeutic agent, autoimmune disease, and/or allergy (as discussed above); these compositions are useful for clearing the circulating protein, peptide or antibody. Accordingly, the compositions of the present disclosure can be used for treating an unwanted immune response, e.g., transplant rejection, an immune response against a therapeutic agent, an autoimmune disease, and/or an allergy, depending on the embodiment.
- an unwanted immune response e.g., transplant rejection, an immune response against a therapeutic agent, an autoimmune disease, and/or an allergy, depending on the embodiment.
- compositions containing a therapeutically effective amount of a composition of the disclosure admixed with at least one pharmaceutically acceptable excipient.
- the disclosure provides methods for the treatment of an unwanted immune response, such as transplant rejection, response against a therapeutic agent, autoimmune disease or allergy.
- an "antigen” is any substance that serves as a target for the receptors of an adaptive immune response, such as the T cell receptor, major histocompatibility complex class I and II, B cell receptor or an antibody.
- an antigen may originate from within the body (e.g., "self,” “auto” or "endogenous").
- an antigen may originate from outside the body ("non-self,” “foreign” or “exogenous”), having entered, for example, by inhalation, ingestion, injection, or transplantation, transdermal ⁇ , etc.
- an exogenous antigen may be biochemically modified in the body.
- Foreign antigens include, but are not limited to, food antigens, animal antigens, plant antigens, environmental antigens, therapeutic agents, as well as antigens present in an allograft transplant.
- an "antigen-binding molecule” as used herein relates to molecules, in particular to proteins such as immunoglobulin molecules, which contain antibody variable regions providing a binding (specific binding in some embodiments) to an epitope.
- the antibody variable region can be present in, for example, a complete antibody, an antibody fragment, and a recombinant derivative of an antibody or antibody fragment.
- Antigen-binding fragments containing antibody variable regions include (without limitation) “Fv”, “Fab”, and “F(ab') 2 " regions, “single domain antibodies (sdAb)", “nanobodies”, “single chain Fv (scFv)” fragments, “tandem scFvs” (V H A-V L A-V H B-V L B), “diabodies”, “triabodies” or “tribodies”, “single- chain diabodies (scDb)", and “bi-specific T-cell engagers (BiTEs)".
- a "chemical modification” refers to a change in the naturally occurring chemical structure of one or more amino acids of a polypeptide. Such modifications can be made to a side chain or a terminus, e.g., changing the amino-terminus or carboxyl terminus. In some embodiments, the modifications are useful for creating chemical groups that can conveniently be used to link the polypeptides to other materials, or to attach a therapeutic agent.
- Constant changes can generally be made to an amino acid sequence without altering activity. These changes are termed “conservative substitutions” or mutations; that is, an amino acid belonging to a grouping of amino acids having a particular size or characteristic can be substituted for another amino acid. Substitutes for an amino acid sequence can be selected from other members of the class to which the amino acid belongs.
- the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, methionine, and tyrosine.
- the polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine.
- the positively charged (basic) amino acids include arginine, lysine and histidine.
- the negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Such substitutions are not expected to substantially affect apparent molecular weight as determined by polyacrylamide gel electrophoresis or isoelectric point. Conservative substitutions also include substituting optical isomers of the sequences for other optical isomers, specifically D amino acids for i_ amino acids for one or more residues of a sequence. Moreover, all of the amino acids in a sequence can undergo a D to L isomer substitution.
- Exemplary conservative substitutions include, but are not limited to, Lys for Arg and vice versa to maintain a positive charge; Glu for Asp and vice versa to maintain a negative charge; Ser for Thr so that a free -OH is maintained; and Gin for Asn to maintain a free -NH 2 .
- Yet another type of conservative substitution constitutes the case where amino acids with desired chemical reactivities are introduced to impart reactive sites for chemical conjugation reactions, if the need for chemical derivatization arises.
- Such amino acids include but are not limited to Cys (to insert a sulfhydryl group), Lys (to insert a primary amine), Asp and Glu (to insert a carboxylic acid group), or specialized noncanonical amino acids containing ketone, azide, alkyne, alkene, and tetrazine side-chains.
- Conservative substitutions or additions of free -NH 2 or -SH bearing amino acids can be particularly advantageous for chemical conjugation with the linkers and galactosylating moieties of Formula 1.
- point mutations, deletions, and insertions of the polypeptide sequences or corresponding nucleic acid sequences can in some cases be made without a loss of function of the polypeptide or nucleic acid fragment.
- Substitutions can include, e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50 or more residues (including any number of substitutions between those listed).
- a variant usable in the present invention may exhibit a total number of up to 200 (e.g., up to 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 1 10, 120, 130, 140, 150, 160, 170, 180, 190, or 200, including any number in between those listed) changes in the amino acid sequence (e.g., exchanges, insertions, deletions, N-terminal truncations, and/or C-terminal truncations).
- the number of changes is greater than 200.
- the variants include polypeptide sequences or corresponding nucleic acid sequences that exhibit a degree of functional equivalence with a reference (e.g., unmodified or native sequence). In several embodiments, the variants exhibit about 80%, about 85%, about 90%, about 95%, about 97%, about 98%, about 99% functional equivalence to an unmodified or native reference sequence (and any degree of functional equivalence between those listed).
- the amino acid residues described herein employ either the single letter amino acid designator or the three-letter abbreviation in keeping with the standard polypeptide nomenclature, J. Biol. Chem., (1969), 243, 3552-3559. All amino acid residue sequences are represented herein by formulae with left and right orientation in the conventional direction of amino- terminus to carboxy-terminus.
- an effective amount refers to that amount of a composition of the disclosure that is sufficient to effect treatment, as defined below, when administered to a mammal in need of such treatment. This amount will vary depending upon the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the particular composition of the disclosure chosen, the dosing regimen to be followed, timing of administration, manner of administration and the like, all of which can readily be determined by one of ordinary skill in the art.
- An “epitope”, also known as antigenic determinant, is the segment of a macromolecule, e.g. a protein, which is recognized by the adaptive immune system, such as by antibodies, B cells, major histocompatibility complex molecules, or T cells.
- An epitope is that part or segment of a macromolecule capable of binding to an antibody or antigen-binding fragment thereof.
- binding in particular relates to a specific binding.
- the term “epitope” refers to the segment of protein or polyprotein that is recognized by the immune system.
- galactose refers to a monosaccharide sugar that exists both in open-chain form and in cyclic form, having D- and L- isomers.
- cyclic form there are two anomers, namely alpha and beta.
- alpha form the C1 alcohol group is in the axial position
- beta form the C1 alcohol group is in the equatorial position.
- galactose refers to the cyclic six-membered pyranose, more in particular the D-isomer and even more particularly the alpha-D-form (a-D- galactopyranose) the formal name for which is (2R,3R,4S,5R,6R)-6-(hydroxymethyl)tetrahydro-2H- pyran-2,3,4,5-tetraol.
- Glucose is an epimer of galactose; the formal name is (2R,3R,4S,5S,6R)-6- (hydroxymethyl)tetrahydro-2/- -pyran-2,3,4,5-tetraol.
- the structure and numbering of galactose and glucose are shown giving two non-limiting examples of stereochemical illustration.
- galactosylating moiety refers to a particular type of liver-targeting moiety.
- Galactosylating moieties include, but are not limited to a galactose, galactosamine and/or N- acetylgalactosamine residue.
- a "glucosylating moiety” refers to another particular type of liver-targeting moiety and includes, but is not limited to glucose, glucosamine and/or N-acetylglucosamine.
- liver-targeting moiety refers to moieties having the ability to direct, e.g., a polypeptide, to the liver.
- the liver comprises different cell types, including but not limited to hepatocytes, sinusoidal epithelial cells, Kupffer cells, stellate cells, and/or dendritic cells.
- a liver-targeting moiety directs a polypeptide to one or more of these cells.
- receptors are present which recognize and specifically bind the liver-targeting moiety.
- Liver-targeting can be achieved by chemical conjugation of an antigen or ligand to a galactosylating or glucosylating moiety, desialylation of an antigen or ligand to expose underlying galactosyl or glucosyl moieties, or specific binding of an endogenous antibody to an antigen or ligand, where the antigen or ligand is: desialylated to expose underlying galactosyl or glucosyl moieties, conjugated to a galactosylating or a glucosylating moiety.
- Naturally occurring desialylated proteins are not encompassed within the scope of certain embodiments of the present disclosure.
- n can be an integer from about 1 to 100 (e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 25, 30, 34, 35, 37, 40, 41 , 45, 50, 54, 55, 59, 60, 65, 70, 75, 80, 82, 83, 85, 88, 90, 95, 99, 100, 105 or 1 10, or any between those listed, including the endpoints of the range) and that the disclosed mixture encompasses ranges such as 1 -4, 2-4, 2-6, 3-8,
- a peptide that specifically binds a particular target is referred to as a "ligand" for that target.
- polypeptide is a term that refers to a chain of amino acid residues, regardless of post- translational modification (e.g., phosphorylation or glycosylation) and/or complexation with additional polypeptides, and/or synthesis into multisubunit complexes with nucleic acids and/or carbohydrates, or other molecules. Proteoglycans therefore also are referred to herein as polypeptides.
- polypeptides can be produced by a number of methods, many of which are well known in the art. For example, polypeptides can be obtained by extraction (e.g., from isolated cells), by expression of a recombinant nucleic acid encoding the polypeptide, or by chemical synthesis. Polypeptides can be produced by, for example, recombinant technology, and expression vectors encoding the polypeptide introduced into host cells (e.g., by transformation or transfection) for expression of the encoded polypeptide
- pharmaceutically acceptable carrier or “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
- the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
- purified refers to a polypeptide that has been chemically synthesized and is thus substantially uncontaminated by other polypeptides, or has been separated or isolated from most other cellular components by which it is naturally accompanied (e.g., other cellular proteins, polynucleotides, or cellular components).
- An example of a purified polypeptide is one that is at least 70%, by dry weight, free from the proteins and naturally occurring organic molecules with which it naturally associates.
- a preparation of a purified polypeptide therefore can be, for example, at least 80%, at least 90%, or at least 99%, by dry weight, the polypeptide.
- Polypeptides also can be engineered to contain a tag sequence (e.g., a polyhistidine tag, a myc tag, a FLAG ® tag, or other affinity tag) that facilitates purification or marking (e.g., capture onto an affinity matrix, visualization under a microscope).
- a purified composition that comprises a polypeptide refers to a purified polypeptide unless otherwise indicated.
- isolated indicates that the polypeptides or nucleic acids of the disclosure are not in their natural environment. Isolated products of the disclosure can thus be contained in a culture supernatant, partially enriched, produced from heterologous sources, cloned in a vector or formulated with a vehicle, etc.
- random copolymer refers to the product of simultaneous polymerization of two or more monomers in admixture, where the probability of finding a given monomeric unit at any given site in a polymer chain is independent of the nature of the neighboring units at that position (Bernoullian distribution).
- the chain can comprise any sequence from 2 up to about 150 W 1 and W 2 groups, such as: -W 1 -W 2 -W 1 -W 2 -; -W 2 -W 1 -W 2 -W 1 -; -W 1 -W 1 -W 1 -W 2 -; -W 1 -W 1 -W 2 -W 2 -; -W 1 -W 2 -W 2 -W 1 -; -W 1 -W 2 -W 2 -W 1 -; -W 1 -W 2 -W 1 -W 2 -W 2 -W 1 -W 2 -W 1 -; -W 1 -W 1 -W 2 -W 2 -W 1 -W 2 -W 1 -; -W 1 -W 1 -W 2 -W 2 -W 1 -W 2 -W 1 -; and W 2 -W 2 -W 1 -W 2 -W 1 -
- sequence identity is used with regard to polypeptide (or nucleic acid) sequence comparisons. This expression in particular refers to a percentage of sequence identity, for example at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% to the respective reference polypeptide or to the respective reference polynucleotide.
- the polypeptide in question and the reference polypeptide exhibit the indicated sequence identity over a continuous stretch of 20, 30, 40, 45, 50, 60, 70, 80, 90, 100 or more amino acids or over the entire length of the reference polypeptide.
- Specific binding refers to a molecule that binds to a target with a relatively high affinity as compared to non-target tissues, and generally involves a plurality of non-covalent interactions, such as electrostatic interactions, van der Waals interactions, hydrogen bonding, and the like. Specific binding interactions characterize antibody-antigen binding, enzyme-substrate binding, and certain protein-receptor interactions; while such molecules might bind tissues besides their specific targets from time to time, to the extent that such non-target binding is inconsequential, the high-affinity binding pair can still fall within the definition of specific binding.
- treatment means any treatment of a disease or disorder in a mammal, including:
- the term "unwanted immune response” refers to a reaction by the immune system of a subject, which in the given situation is not desirable.
- the reaction of the immune system is unwanted if such reaction does not lead to the prevention, reduction, or healing of a disease or disorder but instead causes, enhances or worsens, or is otherwise associated with induction or worsening of a disorder or disease.
- a reaction of the immune system causes, enhances or worsens a disease if it is directed against an inappropriate target.
- an unwanted immune response includes but is not limited to transplant rejection, immune response against a therapeutic agent, autoimmune disease, and allergy or hypersensitivity.
- variant is to be understood as a protein (or nucleic acid) which differs in comparison to the protein from which it is derived by one or more changes in its length, sequence, or structure.
- polypeptide from which a protein variant is derived is also known as the parent polypeptide or polynucleotide.
- variant comprises "fragments” or “derivatives” of the parent molecule. Typically, “fragments” are smaller in length or size than the parent molecule, whilst “derivatives” exhibit one or more differences in their sequence or structure in comparison to the parent molecule.
- modified molecules such as but not limited to post-translationally modified proteins (e.g.
- variants glycosylated, phosphorylated, ubiquitinated, palmitoylated, or proteolytically cleaved proteins
- modified nucleic acids such as methylated DNA.
- variants Naturally occurring and artificially constructed variants are to be understood to be encompassed by the term "variant" as used herein.
- variants usable in the present invention may also be derived from homologs, orthologs, or paralogs of the parent molecule or from artificially constructed variant, provided that the variant exhibits at least one biological activity of the parent molecule, e.g., is functionally active.
- a variant can be characterized by a certain degree of sequence identity to the parent polypeptide from which it is derived. More precisely, a protein variant in the context of the present disclosure may exhibit at least 80% sequence identity to its parent polypeptide. Preferably, the sequence identity of protein variants is over a continuous stretch of 20, 30, 40, 45, 50, 60, 70, 80, 90, 100 or more amino acids. As discussed above, in several embodiments variants exhibit about 80%, about 85%, about 90%, about 95%, about 97%, about 98%, about 99% functional equivalence to an unmodified or native reference sequence (and any degree of functional equivalence between those listed).
- compositions, pharmaceutical formulations, and methods of treatment employing such compositions as represented by Formula 1 :
- n is an integer from about 1 to 100, particularly from about 1 to 20, and most particularly 1 to about 10;
- X is an antigen moiety, particularly a foreign antigen or self-antigen against which a patient develops an unwanted immune response, or a tolerogenic portion (e.g., a fragment or an epitope) of such an antigen moiety;
- Y is a linker moiety or a direct bond, or an antibody, antibody fragment, peptide or other ligand that specifically binds X;
- Z is a liver-targeting moiety, in particular galactosylating or a glucosylating moiety.
- m in Formula 1 will depend upon the nature of X, in that each antigen, antibody, antibody fragment or ligand will have an individual number and density of sites (predominantly the N-terminal amine, lysine residues and cysteine residues) to which a linker, a galactosylating moiety or a glucosylating moiety can be bound.
- Antigens having a limited number of such sites can be derivatized, for example, at the N or C terminus, by adding lysine or cysteine residues (optionally via a cleavable linker, particularly a linker having an immunoproteosome cleavage site).
- compositions of Formula 1 Generally, it is preferred to provide an adequate degree of galactosylation/glucosylation in compositions of Formula 1 so as to facilitate uptake by liver cells.
- Pharmaceutical formulations and methods of the disclosure can employ a cocktail of compositions of Formula 1 , respectively bearing different X moieties (e.g., several epitopes associated with a particular unwanted immune response).
- compositions of Formula 1 include the sub-genuses where X is a foreign transplant antigen against which transplant recipients develop an unwanted immune response (e.g., transplant rejection), a foreign food, animal, plant or environmental antigen against which patients develop an unwanted immune (e.g., transplant rejection), a foreign food, animal, plant or environmental antigen against which patients develop an unwanted immune (e.g.
- Y is a linker of Formulae Ya through Yp; and/or where Z is galactose, galactosamine, N-acetylgalactosamine, glucose, glucosamine or N-acetylglucosamine as illustrated by Formulae 1 a through 1 p as described below with reference to the Reaction Schemes.
- X in the compositions of Formula 1 , can be an antibody, antibody fragment or ligand that specifically binds a circulating protein or peptide or antibody, which circulating protein or peptide or antibody is causatively involved in transplant rejection, immune response against a therapeutic agent, autoimmune disease, hypersensitivity and/or allergy.
- the antigen employed as X in the compositions of Formula 1 can be a protein or a peptide, e.g. the antigen may be a complete or partial therapeutic agent, a full-length transplant protein or peptide thereof, a full-length autoantigen or peptide thereof, a full-length allergen or peptide thereof, and/or a nucleic acid, or a mimetic of an aforementioned antigen.
- the antigen may be a complete or partial therapeutic agent, a full-length transplant protein or peptide thereof, a full-length autoantigen or peptide thereof, a full-length allergen or peptide thereof, and/or a nucleic acid, or a mimetic of an aforementioned antigen.
- a listing of any particular antigen in a category or association with any particular disease or reaction does not preclude that antigen from being considered part of another category or associated with another disease or reaction.
- Antigens employed in the practice of the present disclosure can be one or more of the following:
- Therapeutic agents that are proteins, peptides, antibodies and antibody-like molecules, including antibody fragments and fusion proteins with antibodies and antibody fragments. These include human, non-human (such as mouse) and non-natural (i.e., engineered) proteins, antibodies, chimeric antibodies, humanized antibodies, and non-antibody binding scaffolds, such as fibronectins, DARPins, knottins, and the like.
- Self-antigens that cause an unwanted, autoimmune response.
- the polypeptides employed in the disclosed compositions are typically synthesized exogenously (as opposed to being purified and concentrated from a source of origin).
- the antigen can be a complete protein, a portion of a complete protein, a peptide, or the like, and can be derivatized (as discussed above) for attachment to a linker and/or galactosylating moiety, can be a variant and/or can contain conservative substitutions, particularly maintaining sequence identity, and/or can be desialylated.
- specific antigens can be selected from: Abatacept, Abciximab, Adalimumab, Adenosine deaminase, Ado-trastuzumab emtansine, Agalsidase alfa, Agalsidase beta, Aldeslukin, Alglucerase, Alglucosidase alfa, a-1 -proteinase inhibitor, Anakinra, Anistreplase (anisoylated plasminogen streptokinase activator complex), Antithrombin III, Antithymocyte globulin, Ateplase, Bevacizumab, Bivalirudin, Botulinum toxin type A, Botulinum toxin type B, C1 -esterase inhibitor, Canakinumab, Carboxypeptidase G2 (Glucarpidase
- Particular therapeutic protein, peptide, antibody or antibody-like molecules include Abciximab, Adalimumab, Agalsidase alfa, Agalsidase beta, Aldeslukin, Alglucosidase alfa, Factor VIII, Factor IX, Infliximab, Insulin (including rHu Insulin), L-asparaginase, Laronidase, Natalizumab, Octreotide, Phenylalanine ammonia-lyase (PAL), or Rasburicase (uricase) and generally IgG monoclonal antibodies in their varying formats.
- Another particular group includes the hemostatic agents (Factor VIII and IX), Insulin (including rHu Insulin), and the non-human therapeutics uricase, PAL and asparaginase.
- Unwanted immune response in hematology and transplant includes autoimmune aplastic anemia, transplant rejection (generally), and Graft vs. Host Disease (bone marrow transplant rejection).
- the antigen is a human allograft transplantation antigen
- specific sequences can be selected from: subunits of the various MHC class I and MHC class II haplotype proteins (for example, donor/recipient differences identified in tissue cross-matching), and single-amino-acid polymorphisms on minor blood group antigens including RhCE, Kell, Kidd, Duffy and Ss.
- Such compositions can be prepared individually for a given donor/recipient pair.
- antigen is a self-antigen
- specific antigens can be selected from:
- insulin In type 1 diabetes mellitus, several main antigens have been identified: insulin, proinsulin, preproinsulin, glutamic acid decarboxylase-65 (GAD-65 or glutamate decarboxylase 2), GAD- 67, glucose-6 phosphatase 2 (IGRP or islet-specific glucose 6 phosphatase catalytic subunit related protein), insulinoma-associated protein 2 (IA-2), and insulinoma-associated protein 2 ⁇ ( ⁇ -2 ⁇ ); other antigens include ICA69, ICA12 (SOX-13), carboxypeptidase H, Imogen 38, GLIMA 38, chromogranin-A, HSP-60, carboxypeptidase E, peripherin, glucose transporter 2, hepatocarcinoma-intestine-pancreas/pancreatic associated protein, S100p, glial fibrillary acidic protein, regenerating gene II, pancreatic duodenal homeobox 1 , dystrophia myotonica kinase
- insulin is an example of an antigen that can be characterized both as a self-antigen and a therapeutic protein antigen.
- rHu Insulin and bovine insulin are therapeutic protein antigens (that are the subject of unwanted immune attack), whereas endogenous human insulin is a self-antigen (that is the subject of an unwanted immune attack). Because endogenous human insulin is not available to be employed in a pharmaceutical composition, a recombinant form is employed in certain embodiments of the compositions of the disclosure.
- o Human insulin including an exogenously obtained form useful in the compositions of the disclosure, has the following sequence (UNIPROT P01308):
- o GAD-65 including an exogenously obtained form useful in the compositions of the disclosure, has the following sequence (UNIPROT Q05329):
- o IGRP including an exogenously obtained form useful in the compositions of the disclosure, has the following sequence (UNIPROT QN9QR9):
- main antigens include thyroglobulin (TG), thyroid peroxidase (TPO) and thyrotropin receptor (TSHR); other antigens include sodium iodine symporter (NIS) and megalin.
- TG thyroglobulin
- TPO thyroid peroxidase
- TSHR thyrotropin receptor
- NIS sodium iodine symporter
- an antigen is insulin-like growth factor 1 receptor.
- a main antigen is calcium sensitive receptor.
- main antigens include 21 -hydroxylase, 17a-hydroxylase, and P450 side chain cleavage enzyme (P450scc); other antigens include ACTH receptor, P450c21 and P450c17.
- P450scc P450 side chain cleavage enzyme
- main antigens include FSH receptor and a-enolase.
- main antigens include pituitary gland-specific protein factor (PGSF) 1a and 2; another antigen is type 2 iodothyronine deiodinase.
- PGSF pituitary gland-specific protein factor
- main antigens include myelin basic protein (“MBP”), myelin oligodendrocyte glycoprotein (“MOG”) and myelin proteolipid protein (“PLP”).
- MBP myelin basic protein
- MOG myelin oligodendrocyte glycoprotein
- PGP myelin proteolipid protein
- o MBP including an exogenously obtained form useful in the compositions of the disclosure, has the following sequence (UNIPROT P02686):
- o MOG including an exogenously obtained form useful in the compositions of the disclosure, has the following sequence (UNIPROT Q16653):
- o PLP including an exogenously obtained form useful in the compositions of the disclosure, has the following sequence (UNIPROT P60201 ):
- o Peptides/epitopes useful in the compositions of the disclosure for treating multiple sclerosis include some or all of the following sequences, individually in a composition of Formula 1 or together in a cocktail of compositions of Formula 1 :
- ⁇ MBP13-32 KYLATASTMDHARHGFLPRH (SEQ ID NO:7);
- ⁇ MBP146-170 AQGTLSKIFKLGGRDSRSGSPMARR (SEQ ID NO: 10);
- MOG1 -20 GQFRVIGPRHPIRALVGDEV (SEQ ID NO: 1 1);
- MOG35-55 MEVGWYRPPFSRWHLYRNGK (SEQ ID NO: 12);
- ⁇ PLP139-154 HCLGKWLGHPDKFVGI (SEQ ID NO: 13).
- main antigens include collagen II, immunoglobulin binding protein, the fragment crystallizable region of immunoglobulin G, double-stranded DNA, and the natural and cirtullinated forms of proteins implicated in rheumatoid arthritis pathology, including fibrin/fibrinogen, vimentin, collagen I and II, and alpha-enolase.
- a main antigen is H+,K+-ATPase.
- main antigens are tissue transglutaminase and the natural and deamidated forms of gluten or gluten-like proteins, such as alpha-, gamma-, and omega-gliadin, glutenin, hordein, secalin, and avenin.
- alpha gliadin turns more immunogenic in the body through deamidation by tissue glutaminase converting alpha gliadin's glutamines to glutamic acid.
- alpha gliadin is originally a foreign food antigen, once it has been modified in the body to become more immunogenic it can be characterized as a self-antigen.
- a main antigen is tyrosinase, and tyrosinase related protein 1 and 2.
- o Tyrosinase including an exogenously obtained form useful in the compositions of the disclosure, has the following sequence (UNIPROT P14679):
- o Melanocyte protein PMEL, gp100 including an exogenously obtained form useful in the compositions of the disclosure, has the following sequence (UNIPROT P40967):
- acetylcholine receptor In myasthenia gravis, a main antigen is acetylcholine receptor.
- main antigens are desmoglein 3, 1 and 4; other antigens include pemphaxin, desmocollins, plakoglobin, perplakin, desmoplakins, and acetylcholine receptor.
- main antigens include BP180 and BP230; other antigens include plectin and laminin 5.
- main antigens include endomysium and tissue transglutaminase.
- a main antigen is collagen VII.
- main antigens include matrix metalloproteinase 1 and 3, the collagen- specific molecular chaperone heat-shock protein 47, fibrillin-1 , and PDGF receptor; other antigens include Scl-70, U1 RNP, Th/To, Ku, Jo1 , NAG-2, centromere proteins, topoisomerase I, nucleolar proteins, RNA polymerase I, II and III, PM-SIc, fibrillarin, and B23.
- a main antigen is Ul snRNP.
- the main antigens are nuclear antigens SS-A and SS-B; other antigens include fodrin, poly(ADP-ribose) polymerase and topoisomerase, muscarinic receptors, and the Fc-gamma receptor 1Mb.
- main antigens include nuclear proteins including the "Smith antigen," SS-A, high mobility group box 1 (HMGB1 ), nucleosomes, histone proteins and double- stranded DNA (against which auto-antibodies are made in the disease process).
- SS-A nuclear proteins
- HMGB1 high mobility group box 1
- nucleosomes nucleosomes
- histone proteins double- stranded DNA (against which auto-antibodies are made in the disease process).
- main antigens include glomerular basement membrane proteins including collagen IV.
- a main antigen is cardiac myosin.
- autoimmune polyendocrine syndrome type 1 antigens include aromatic L-amino acid decarboxylase, histidine decarboxylase, cysteine sulfinic acid decarboxylase, tryptophan hydroxylase, tyrosine hydroxylase, phenylalanine hydroxylase, hepatic P450 cytochromes P4501A2 and 2A6, SOX-9, SOX-10, calcium-sensing receptor protein, and the type 1 interferons interferon alpha, beta and omega.
- AQP4 AQP4.
- o Aquaporin-4 including an exogenously obtained form useful in the compositions of the disclosure, has the following sequence (UNIPROT P55087):
- VHVI DVDRGEEKKGKDQSGEVLSSV (SEQ ID NO: 17).
- main antigens include Retinal S-antigen or "S-arrestin” and interphotoreceptor retinoid binding protein (IRBP) or retinol-binding protein 3.
- IRBP interphotoreceptor retinoid binding protein
- o S-arrestin including an exogenously obtained form useful in the compositions of the disclosure, has the following sequence (UNIPROT P10523):
- o IRBP including an exogenously obtained form useful in the compositions of the disclosure, has the following sequence (UNIPROT P10745):
- antigen is a foreign antigen against which an unwanted immune response can be developed, such as food antigens
- specific antigens can be:
- conarachin (Ara h 1 ), allergen II (Ara h 2), arachis agglutinin, conglutin (Ara h 6); o conarachin, for example has the sequence identified as UNIPROT Q6PSU6
- high molecular weight glutenin from wheat and/or other cereals: high molecular weight glutenin, low molecular weight glutenin, alpha-, gamma- and omega-gliadin, hordein, secalin and/or avenin;
- o peptides/epitopes useful in the compositions of the disclosure for treating Celiac Disease include some or all of the following sequences, individually in a composition of Formula 1 or together in a cocktail of compositions of Formula 1 :
- LQLQPFPQPELPYPQPELPYPQPELPYPQPQPF (SEQ ID NO:21 )
- antigen is a foreign antigen against which an unwanted immune response is developed, such as to animal, plant and environmental antigens
- specific antigens can, for example, be: cat, mouse, dog, horse, bee, dust, tree and goldenrod, including the following proteins or peptides derived from:
- weeds including ragweed allergens amb a 1 , 2, 3, 5, and 6, and Amb t 5; pigweed Che a 2 and 5; and other weed allergens Par j 1 , 2, and 3, and Par o 1 );
- grass including major allergens Cyn d 1 , 7, and 12; Dac g 1 , 2, and 5; Hoi I 1.01203; Lol p 1 , 2, 3, 5, and 1 1 ; Mer a 1 ; Pha a 1 ; Poa p 1 and 5);
- pollen from ragweed and other weeds including curly dock, lambs quarters, pigweed, plantain, sheep sorrel, and sagebrush
- grass including Bermuda, Johnson, Kentucky, Orchard, Sweet vernal, and Timothy grass
- trees including catalpa, elm, hickory, olive, pecan, sycamore, and walnut
- pets including cats, dogs, rodents, and farm animals;
- major cat allergens include Fel d 1 through 8, cat IgA, BLa g 2, and cat albumin;
- major dog allergens include Can f 1 through 6, and dog albumin);
- bee stings including major allergens Api m 1 through 12;
- fungus including allergens derived from, species of Aspergillus and Penicillium, as well as the species Alternaria alternata, Davidiella tassiana, and Trichophyton rubrum.
- a patient can be tested to identify an antigen against which an unwanted immune response has developed, and a protein, peptide or the like can be developed based on that antigen and incorporated as X in a composition of the present disclosure.
- antigens antibodies, antibody fragments having sialylation that can be removed to leave glycosylation specifically targeting the ASGPR: follicle stimulating hormone (FSH), human chorionic gonadotropin (HCG), luteinizing hormone (LH), osteopontin, thyroid stimulating hormone (TSH), agalsidase alfa, agalsidase beta (FABRAZYME®; Genzyme), epoetin alfa and epoetin beta, follitropin alfa (GONAL-F®; Merck/Serono) and follitropin beta (FOLLISTIM®; Schering-Plough), insulin growth factor binding protein 6 (IGFBP-6), lutropin alfa (LUVERIS®; Merck/Serono), transforming growth factor ⁇ 1 , antithrombin (ATry n®/TRO M BATE-I II®; Genzyme/Talecris Bio
- FSH follicle stimulating hormone
- Pharmaceutically relevant proteins that have previously been hyperglycosylated and can be desialylated for hepatocyte-ASGPR targeting include: interferon alfa and gamma, luteinizing hormone, Fv antibody fragments, asparaginase, cholinesterase, darbepoetin alfa (AraNESP®; Amgen), thrombopoietin, leptin, FSH, IFN-a2, serum albumin, and corifollitropin alfa.
- Proteins with glycans that do not normally terminate in sialic acids including proteins produced in bacteria or yeast (such as arginase, some insulins, and uricase) would not be amenable to desialylation.
- such moieties are chosen to specifically bind a targeted circulating protein or peptide or antibody, and result in hepatic uptake of the circulating targeted moiety, possibly as an adduct with the targeting moiety, ultimately resulting in the clearance and inactivation of the circulating targeted moiety.
- a targeted circulating protein or peptide or antibody for example, liver-targeted Factor VIII will bind and clear circulating anti-Factor VIII antibodies. Procedures for the identification of such moieties will be familiar to those skilled in the art.
- the linkers employed in the compositions of the present disclosure (“Y" in Formula 1 ) can include N-hydroxysuccinamidyl linkers, malaemide linkers, vinylsulfone linkers, pyridyl di-thiol- poly(ethylene glycol) linkers, pyridyl di-thiol linkers, n-nitrophenyl carbonate linkers, NHS-ester linkers, nitrophenoxy poly(ethylene glycol)ester linkers and the like.
- linkers comprises linkers of Formula Y'-CMP below (where Y' indicates the remaining portion of the linker and R 9 and Z are as defined). More particularly, in the group of linkers including Formula Y'-CMP, in several embodiments the R 9 substituent is an ethylacetamido group, and even more particularly the ethylacetamido is conjugated with C1 of N-acetylgalactosamine or N-acetylglucosamine.
- Di-thiol-containing linkers particularly disulfanylethyl carbamate-containing linkers (named including a free amine of X, otherwise named a "disulfanyl ethyl ester" without including the free amine of X) are particularly advantageous in the present compositions as having the ability to cleave and release an antigen in its original form once inside a cell, for example as illustrated below (where Y' indicates the remaining portion of the linker and X' and Z are as defined).
- n is an integer representing a mixture including from about 1 to 100, particularly about 8 to 90 (e.g., 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 70, 75, 80, 85, 90 or 95), more particularly about 40 to 80 (e.g., 39, 40, 43, 45, 46, 48, 50, 52, 53, 55, 57, 60, 62, 65, 66, 68, 70, 73, 75, 78, 80 or 81 ) ethylene glycol groups, where the mixture typically encompasses the integer specified as n ⁇ 10%;
- p is an integer representing a mixture including from about 2 to 150, particularly about 20 to 100 (e.g., 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 70, 75, 80, 85, 90, 95, 100 or 105) and more particularly about 30 to 40 (e.g., 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43 or 44), where the mixture typically encompasses the integer specified as p ⁇ 10%;
- q is an integer representing a mixture including from about 1 to 44, particularly about 3 to 20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22) and more particularly about 4 to 12 (e.g., 4, 5, 6, 7, 8, 9, 10, 11 , 12 or 13), where the mixture typically encompasses the integer specified as q ⁇ 10%; and
- R 8 is -CH 2 - ("methyl”) or -CH 2 -CH 2 -C(CH 3 )(CN)- ("1 -cyano-1 -methyl-propyl" or "CMP").
- Y' represents the remaining portion of Y (e.g., HS-PEG).
- W represents a polymer of the same W 1 group, or W is a copolymer (preferably a random copolymer) of the same or different W 1 and W 2 groups, where:
- p is an integer from 2 to about 150;
- R 9 is a direct bond, -CH 2 -CH 2 — NH-C(O)- (i.e., an ethylacetamido group or "EtAcN”) or -CH2-CH 2 -(0-CH2-CH 2 )t-NH-C(0)- (i.e., a pegylated ethylacetamido group or "Et- PEGt-AcN”)
- t is an integer from 1 to 5, (particularly 1 to 3, and more particularly 1 or 2);
- R 10 is an aliphatic group, an alcohol or an aliphatic alcohol, particularly N-(2- hydroxypropyl)methylacrylamide;
- Z (not shown) is galactose, glucose, galactosamine, glucosamine, N- acetylgalactosamine or N-acetylglucosamine.
- Linkers of Formula Yn can be synthesized via certain precursors that render Yn particularly suitable for conjugation to hydrophobic antigens.
- linkers shown above as Formulae Yh through Yn are synthesized as isomers that are employed without separation.
- the linkers of Formulae Yh, Yi, Yj and Yn will be a mixture of the 8,9-dihydro-1H-dibenzo[i),/][1 ,2,3]triazolo[4,5-d]azocin-8yl and 8,9-dihydro-3H- dibenzo[b, ][1 ,2,3]triazolo[4,5-d]azocin-8yl structures illustrated below:
- linkers of Formulae Yk, YL and Ym will be a mixture of the 8,9-dihydro-1 H- dibenzo[3,4:7,8]cycloocta[1 ,2-d][1 ,2,3]triazol-8-yl and 8,9-dihydro-1 H-dibenzo[3,4:7,8]cycloocta[1 ,2- d][1 ,2,3]triazol-9-yl stru
- the galactosylating moieties employed in the compositions of the present disclosure serve to target the compositions to liver cells (for example, specifically binding hepatocytes) and can be selected from: galactose, galactosamine or N-acetylgalactosamine.
- the glucosylating moieties employed in the compositions of the present disclosure serve to target the compositions to liver cells (for example, specifically binding hepatocytes or LSECs) and can be selected from: glucose, glucosamine or N-acetylglucosamine.
- liver-targeting moieties include galactose or glucose conjugated at C1 or C6, galactosamine or glucosamine conjugated at C2, and N-acetylgalactosamine or N-acetylglucosamine conjugated at C6.
- Other particular liver-targeting moieties include N-acetylgalactosamine or N- acetylglucosamine conjugated at C2, more particularly conjugated to a linker bearing an R 9 substituent that is CH 2 .
- liver-targeting moieties include galactose, galactosamine, N-acetylgalactosamine, glucose, glucosamine or N-acetylglucosamine conjugated at C1 , more particularly conjugated to a linker bearing an R 9 substituent that is an ethylacetamido group.
- compositions of Formula 1 can be named using a combination of lUPAC and trivial names.
- Y is Formula Ya
- m is 1
- n is 4
- Z is N- acetylgalactosamin-2-yl or N-acetylglucosamin-2-yl:
- composition of the disclosure where X' is tissue transglutaminase, m is 2, n is 4 and Z' is N- acetylgalactosamin-2-yl or N-acetylglucosamin-2-yl can be named (3Z)-((tissue transgultaminase)-1 ,3- diylbis(1 -oxo-1 -((2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)-4,7, 10, 13-tetraoxa- 16, 17-dithiahenicosan-21 -yl-21 -ylidene))bis(triaz-1 -yn-2-ium) chloride.
- compositions of Formula 1 can be named using an alternative naming system by reference to X and correspondence to one of Formulae 1 a to 1 p (as illustrated in the reaction schemes) followed by recitation of the integers for variables m, n, p and/or q, R , R and identification of the galactosylating moiety and the position at which it is conjugated.
- the compounds where W is a copolymer are designated by the letter of the "Y group” followed by a "prime” (e.g., F1 c') and include the number and an identification of the comonomers.
- composition of Formula 1 a where X is ovalbumin, m is 2, n is 4 and Z is N- acetylgalactosamin-2-yl can be named "F1 a-OVA-m 2 -n 4 -2NAcGAL.”
- the corresponding composition of Formula 1 a where X is ovalbumin, m is 2, n is 4 and Z is N-acetylglucosamin-2-yl can be named "F1 a- OVA-m 2 -n 4 -2NAcGLU.”
- both isomers can be named "Fl n-insulin-m ⁇ n ⁇ Pi-q ⁇ CMP-EtAcN-I NAcGAL" (or ""Fl n-insulin-mi-ni-pi-q ⁇ CMP-EtAcN-I NAcGLU" because no stereochemistry is shown for the sugar ring) where CMP indicates that R 8 is 1 -cyano-1 -methyl-propyl, EtAcN indicates that R 9 is ethylacetamido and I NAcGAL indicates Z" is N-acetylgalactosamine conjugated at C1. Absence of the abbreviation EtAcN before the designation for Z would indicate that R 9 is a direct bond.
- composition of Formula 1 exemplifies compounds where W is a copolymer :
- the compound can be named "F1 c'-DQ8-relevant Alpha Gliadin-rrvn ⁇ p t-CMP-poly ⁇ EtPEGiAcN-l NAcGLU 2 -HPMA 2 )".
- compositions of Formula 1 can be prepared, for example, by adjusting the procedures described in Zhu, L, et al., Bioconjugate Chem. 2010, 27, 21 19-2127. Syntheses of certain compositions of Formula 1 are also described below with reference to Reaction Schemes 1 to 14. Other synthetic approaches will be apparent to those skilled in the art.
- R 1 is a free surface amino (-NH 2 ) or thiol (-SH) moiety positioned on X's three-dimensional structure so as to be accessible for conjugation to a linker, and X' represents the remainder of X excluding the identified free amino group(s) [(X" is used in the reaction schemes to represent the remainder of X excluding free thiol group(s)].
- X there will be at least one (the N-terminal amine) and can be multiple R 1 groups (predominantly from lysine residues or cysteine residues that are not involved in disulfide bonding), as represented by m, which is an integer from about 1 to 100, more typically 1 or from about 4 to 20, and most typically 1 to about 10.
- R 1 groups randominantly from lysine residues or cysteine residues that are not involved in disulfide bonding
- m which is an integer from about 1 to 100, more typically 1 or from about 4 to 20, and most typically 1 to about 10.
- R 2 is OH or a protecting group
- R 3 is OH, NH 2 , NHAc, a protecting group or NH-protecting group
- R 4 is OH or a protecting group
- R 5 is OH or a protecting group
- R 6 is OH or a protecting group
- Z' is galactose or glucose conjugated at C1 or C6, galactosamine or glucosamine conjugated at C2, or N-acetylgalactosamine conjugated or N-acetylglucosamine at C6;
- R 8 is -CH 2 - or -CH 2 -CH 2 -C(CH 3 )(CN)-;
- R 9 is a direct bond and Z" is N-acetylgalactosamine conjugated at C2;
- R 9 is an ethylacetamido or a pegylated ethylacetamido group and Z" is galactose, glucose, galactosamine, glucosamine, N-acetylgalactosamine or N-acetylglucosamine conjugated at C1.
- solvent inert under the conditions of the reaction being described in conjunction therewith [including, for example, benzene, toluene, acetonitrile, tetrahydrofuran (“THF”), dimethylformamide (“DMF”), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, pyridine and the like].
- solvents used in the reactions of the present disclosure are inert organic solvents.
- q.s means adding a quantity sufficient to achieve a stated function, e.g., to bring a solution to the desired volume (i.e., 100%).
- Isolation and purification of the compounds and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography or thick-layer chromatography, centrifugal size exclusion chromatography, high-performance liquid chromatography, recrystallization, sublimation, fast protein liquid chromatography, gel electrophoresis, dialysis, or a combination of these procedures.
- suitable separation and isolation procedures can be had by reference to the examples hereinbelow. However, other equivalent separation or isolation procedures can, of course, also be used.
- Reaction Scheme 1 illustrates the preparation of compositions of Formula 1 where Z can be galactose, glucose, galactosamine, glucosamine, N-acetylgalactosamine or N-acetylglucosamine.
- Z' as employed in Reaction Scheme 1 encompasses galactose or glucose conjugated at C1 and C6 and corresponding to the following structures according to Formula 1 :
- a pyridyl di-thiol-poly(ethylene glycol)-NHS ester (Formula 104) is contacted with galactosamine or glucosamine (Formula 105 where R 3 is NH 2 and R 2 , R 4 , R 5 and R 6 are OH) with stirring at about pH 8 for about 1 hour to give the corresponding pyridyl di-thiol- poly(ethylene glycol)-sugar of Formula 106A, which can be used without further purification.
- Step 4 the acid of Formula 109 is contacted with a protected galactose or N-acetylgalactosamine of Formula 105 where R 2 is OH and R 3 , R 4 , R 5 and R 6 are protecting groups ("PG"), where R 6 is OH and R 2 , R 3 , R 4 and R 5 are PG, or where R 6 is N-acetyl and R 2 , R 3 , R 4 and R 5 are PG to give the corresponding pyridyl di-thiol-poly(ethylene glycol)-sugars of Formulae 106B, 106C and 106D, which can be used following de-protection.
- R 2 is OH and R 3 , R 4 , R 5 and R 6 are protecting groups
- PG protecting groups
- Step 5 to a stirred solution of the product of Step 1 (Formula 103') is added an excess (corresponding to the value of m) of the product of Step 2 or Step 4 (Formula 106, i.e., 106A, 106B, 106C or 106D) for about 1 hour, followed by centrifugal sized exclusion chromatography to remove any free remaining reactants to yield the corresponding product according to Formula 1 a, respectively, Formula 1 aA, Formula 1 aB, Formula 1 aC and Formula 1 aD.
- compositions corresponding to Formula 1 a can be named, respectively, e.g., as follows:
- Reaction Schemes 2-14 illustrate preparation of the compounds where W is a polymer of the same W 1 group.
- Z refers to N-acetylgalactosamine or N-acetylglucosamine conjugated at C2:
- the C1 conjugated compositions can be protected during synthesis, for example by cyclizing the amine with the C3 hydroxyl and de-protecting following incorporation of the protected galactosamine into the adjacent portion of the linker.
- the poly(galactose methacrylate) and poly(glucose methacrylate) reactants of Formulae 201 , 401 , 501 , 601 , 701 , 803 and 1401 can be prepared by methacrylating galactose or glucose, e.g., contacting galactosamine or glucosamine and methacrylate anhydride, followed by reversible addition- fragmentation chain transfer (RAFT) polymerization with a corresponding RAFT agent in the presence of azobisisobutyronitrile (AIBN) in a suitable solvent, starting with freeze-thaw cycles followed by heating at about 60-80°C, preferably 70°C for about 5-8, preferably about 6 hours.
- the polymer can be precipitated in a lower alkanol, preferably methanol.
- compositions of Formula 1 b can be named as follows:
- composition of Formula 1 b where X' is uricase, m is 1 , n is 4, p is 4 and Z" is N- acetylgalactosamine conjugated at C2 can be named "Fl b-uricase-nvn ⁇ p ⁇ NAcGAL" or "30-(uricase)- 3,5J,9-tetramethyl-12-oxo-1 -phenyl-1 -thioxo-3,5,7,9-tetrakis((2,4,5-trihydroxy-6- (hydroxymethyl)tetrahydro-2H-pyran-3-yl)carbamoyl)-13, 16, 19,22-tetraoxa-2,25,26-trithiatriacontan-30- iminium".
- an antigen, antibody, antibody fragment or ligand having native free surface thiol group(s) (cysteines) [Formula 101 " corresponding to Formula 101 and illustrating where X", as the term will be subsequently employed, represents X excluding the identified free surface thiol group(s)] is contacted with an excess (corresponding to the value of m) of a pyridyl di- thiol-poly(ethylene glycol) of Formula 201 to yield the corresponding product according to Formula 1 c.
- compositions corresponding to Formula 1 c can be named as follows:
- an antigen, antibody, antibody fragment or ligand having native free surface thiol group(s) of Formula 101 " is contacted with an excess (corresponding to the value of m) of a pyridyl di-thiol of Formula 401 to yield the corresponding product according to Formula 1 d.
- compositions corresponding to Formula 1 d can be named as follows:
- compositions corresponding to Formula 1 e can be named as follows:
- an antigen, antibody, antibody fragment or ligand having native free surface amino group(s) of Formula 101 ' is contacted with an excess (corresponding to the value of m) of a n-nitrophenyl carbonate poly(ethylene glycol)ester of Formula 601 to yield the corresponding product according to Formula 1f.
- compositions corresponding to Formula 1f can be named as follows:
- an antigen, antibody, antibody fragment or ligand having native free surface amino group(s) of Formula 101 ' is contacted with an excess (corresponding to the value of m) of a NHS-ester poly(ethylene glycol)ester of Formula 701 to yield the corresponding product according to Formula 1 g.
- the compositions corresponding to Formula 1 g can be named as follows:
- Step 1 an antigen, antibody, antibody fragment or ligand having native free surface amino group(s) of Formula 101 ' is contacted with an excess (corresponding to the value of m) of an amine-reactive linker for Click chemistry of Formula 801 to yield the corresponding product according to Formula 802.
- Step 2 the product of Formula 802 is then contacted with an equivalent amount (again corresponding to the value of m) of a galactos(amine) polymer of Formula 803 to yield the corresponding isomeric product according to Formula 1 h.
- the two isomers, illustrated above, result from non-specific cyclization of the azide of Formula 803 with the triple bond of Formula 802. Such non-specific cyclization occurs in the synthesis of other compositions where Y is selected from Formulae Yh through Yn, but will not be illustrated in each instance.
- compositions corresponding to Formula 1 h can be named as follows:
- Step 1 an antigen, antibody, antibody fragment or ligand having native free surface thiol group(s) of Formula 101 " is contacted with an excess (corresponding to the value of m) of a thiol-reactive linker for Click chemistry of Formula 901 to yield the corresponding product according to Formula 902".
- Step 2 the product of Formula 902" is then contacted with an equivalent amount (again corresponding to the value of m) of a galactos(amine) polymer of Formula 803 to yield the corresponding isomeric product according to Formula 1 i.
- compositions corresponding to Formula 1 i can be named as follows:
- compositions corresponding to Formula 1j can be named as follows:
- Step 1 an antigen, antibody, antibody fragment or ligand having native free surface thiol group(s) of Formula 101 " is contacted with an excess (corresponding to the value of m) of a thiol-reactive linker for Click chemistry of Formula 1001 to yield the corresponding product according to Formula 1002.
- Step 2 the product of Formula 1002 is then contacted with an equivalent amount (again corresponding to the value of m) of a galactos(amine) polymer of Formula 803 to yield the corresponding isomeric product according to Formula 1 k.
- compositions corresponding to Formula 1 k can be named as follows:
- compositions corresponding to Formula 1 i_ can be named as follows:
- an azide-modified uRAFT agent (Formula 1 106) is added to a solution of the product of Formula 1 105 with azobisisobutyronitrile, subjected to 4 free-pump-thaw cycles and then stirred at 70°C. After several hours the corresponding polymer product of Formula 1 107 is precipitated by addition of a lower alkanol followed by solvent removal.
- R 3 is NH-protecting group (e.g., cyclized with R 4 ) the protecting group(s) is(are) removed at this point.
- an antigen, antibody, antibody fragment or ligand having native free surface amino group(s) of Formula 101 ' is added to a pH 8.0 buffer and contacted with an excess (corresponding to the value of m) of a dioxopyrrolidine of Formula 1 108 with stirring. After 1 hour, unreacted Formula 1 108 is removed and the resulting product of Formula 1 109 is used without further purification.
- compositions corresponding to Formula 1 m can be named as follows:
- Reaction Scheme 12 The synthetic approach of Reaction Scheme 12 is particularly suitable for hydrophobic antigens, antibodies, antibody fragments and ligands (e.g., Insulin) due to the use of organic solvents.
- ligands e.g., Insulin
- Step 1 an antigen, antibody, antibody fragment or Iigand having native free surface amino group(s) of Formula 101 ' is dissolved in an organic solvent (e.g., DMF) containing triethylamine. To this is added an amount (corresponding to the value of m) of a compound of Formula 1201 followed by stirring and the addition of t-butyl methyl ether. The corresponding product of Formula 1202 is recovered as a precipitate.
- an organic solvent e.g., DMF
- the product of Formula 1202 is resuspended in the organic solvent and an amount (corresponding to the value of m) of Formula 1 107 (obtained, e.g., as described with reference to Reaction Scheme 1 1) is added followed by stirring.
- the reaction product is precipitated via the addition of dichloromethane, followed by filtration and solvent removal. Purification (e.g., resuspension in PBS followed by centrifugal size exclusion chromatography yields the corresponding isomeric product of Formula 1 n.
- compositions corresponding to Formula 1 n can be named as follows:
- Step 1 a nitrophenoxycarbonyl-oxyalkyl di-thiol-poly(ethylene glycol)-NHS ester (Formula 1301 ) is contacted with galactose, galactosamine or N-acetylgalactosamine (Formula 105) to give the corresponding product of Formula 1302, along with the other two illustrated products, from which the desired nitrophenoxycarbonyl di-thiol-poly(ethylene glycol)-carboxyethyl galactose, galactosamine or N-acetylgalactosamine of Formula 1302 is isolated before proceeding to the next step.
- an antigen, antibody, antibody fragment or ligand having native free surface amino group(s) of Formula 101 ' is contacted with an excess (corresponding to the value of m) of the product of Formula 1302 to yield the corresponding product according to Formula 1o.
- compositions corresponding to Formula 1 o can be named as follows:
- an antigen, antibody, antibody fragment or ligand having native free surface amino group(s) (Formula 101 ') is contacted with an excess (corresponding to the value of m) of a pyridyl di-thiol-poly(ethylene glycol)-NHS ester of Formula 1401 to yield the corresponding product according to Formula 1 p.
- compositions corresponding to Formula 1 p can be named as follows:
- Reaction Schemes 15-18 illustrate preparation of the compounds where W is a copolymer of the same or different W 1 and W 2 groups.
- Step 1 galactose or glucose (Formula1 101 where R 3 and R 4 are OH), protected galactosamine or protected glucosamine (Formula 1 101 where R 3 is NH- protecting group, e.g., cyclized with R 4 ) or N-acetyl-D-galactosamine or N-acetyl-D-glucosamine (Formula1 101 where R 3 is NHAc and R 4 is OH) is contacted with a 2-(poly-(2- chloroethoxy)ethoxy)ethan-1 -ol of Formula 1501 (where t is 1 to 5) followed by cooling and the dropwise addition of acetylchloride. The solution is warmed to room temperature and then heated to 70°C for several hours. Ethanol is added to the crude product and the resulting solution is stirred in the presence of carbon and then filtered followed by solvent removal to yield the corresponding product of Formula 1502.
- the product of Formula 1504 is added to a solution of methacrylate anhydride. Triethylamine is added and the reaction stirred for 2 hours followed by solvent removal and isolation to yield the corresponding product of Formula 1505. Alternatively, pentafluorophenyl methacrylate (or another acrylating agent) can be used to prepare the corresponding product of Formula 1505. In some embodiments, the product of formula 1504 is added to DMF. Triethyl amine (e.g., an organic base) is added and the mixture is cooled (e.g., to 4°C using an ice bath).
- Triethyl amine e.g., an organic base
- pentafluorophenyl methacrylate (or another acrylating agent) is added (e.g., drop-wise with constant stirring). After a period of time (e.g., 30 minutes), the cooling (e.g., ice-bath) is removed and the reaction is allowed to stir at room temperature for a period of time (e.g., 4 hours). In some embodiments, the solvent is then removed. In some embodiments, the product is purified using flash chromatography.
- an azide-modified uRAFT agent of Formula 1 106 and a methacrylamide of Formula 1506 are added to a solution of the product of Formula 1505 with azobisisobutyronitrile, subjected to 4 free-pump-thaw cycles and then stirred at 70°C. After several hours the corresponding random copolymer product of Formula 1507 is precipitated by addition of a lower alkanol or acetone followed by solvent removal.
- R 3 is NH-protecting group (e.g. , cyclized with R 4 ) the protecting group(s) is(are) removed at this point.
- Step 6 the product of Formula 1507 is added to a pH 8.0 buffer, to which is added the product of Formula 1 109 (prepared, for example, as described with reference to Reaction Scheme 1 1 ). After stirring for 2 hours, the excess Formula 1 109 is removed to yield the corresponding isomeric random copolymer product of Formula 1 m'.
- compositions corresponding to Formula 1 m' can be named as follows:
- Step 1 a compound of Formula 1601 is contacted with compounds of Formulae 1505 and 1506 under conditions analogous to those of Reaction Scheme 15, Step 5, to afford the corresponding compound of Formula 1602.
- t is an integer from about 1 to about 10 or about 1 to about 5.
- an oligoethylene glycol (1650) is reacted with p-toluenesulfonyl chloride (or some other agent capable of functionalizing 1650 with a leaving group) to form oligoethylene glycol mono p- toluenesulfonate (1651 )(or some other oligoethylene glycol functionalized with a leaving group).
- compound 1651 can be reacted with potassium thioacetate to form compound
- compound 1652 is reacted with 2,2-dithiodipyridine to form compound
- compound 1653 is coupled to compound 1654 to form compound 1601 a.
- compositions corresponding to Formula 1 c' can be named as follows:
- Step 1 a compound of Formula 600' is contacted with compounds of Formulae 1505 and 1506 under conditions analogous to those of Reaction Scheme 15, Step 5, to afford the corresponding compound of Formula 601 '.
- compositions corresponding to Formula 1f can be named as follows:
- compositions corresponding to Formula 1 g' can be named as follows:
- a compound of Formula 103' is contacted with an excess (corresponding to the value of m) of a compound of Formula 106 to give the corresponding product of Formula 1 a.
- a compound of Formula 103' is contacted with an excess (corresponding to the value of m) of a compound of Formula 201 to give the corresponding product of Formula 1 b.
- a compound of Formula 802, 902 or 1002 is contacted with an excess (corresponding to the value of m) of a compound of Formula 803 to give the corresponding product of Formula 1 h, Formula 1 i or Formula 1 k, respectively.
- a compound of Formula 1 109 is contacted with an excess (corresponding to the value of m) of a compound of Formula 1 107 to give the corresponding product of Formula 1 m, particularly where n is about 80, p is about 30, q is about 4, and m being a function of the antigen is about 2 to 10.
- a compound of Formula 1202 is contacted with an excess (corresponding to the value of m) of a compound of Formula 1 107 to give the corresponding product of Formula 1 n, particularly where n is about 1 , p is about 30, q is about 4, and m being a function of the antigen is about 2 to 10.
- a compound of Formula 1507 is contacted with a compound of Formula 1 109 to give the corresponding product of Formula 1 m', particularly where n is about 4, p is about 90, q is about 4, t is about 1 or 2, R 3 is NHAc, R 4 is OH, R 8 is CMP, R 10 is 2-hydroxypropyl and m being a function of the antigen is about 1 to 10.
- a compound of Formula 101 " is contacted with a compound of Formula 1602 to give the corresponding product of Formula 1 c', particularly where n is about 4, p is about 90, t is about 1 or 2, R 3 is NHAc, R 4 is OH, R 8 is CMP, R 10 is 2-hydroxypropyl and m being a function of the antigen is about 1 to 10.
- a compound of Formula 101 ' is contacted with a compound of Formula 601 ' to give the corresponding product of Formula 1f, particularly where n is about 4, p is about 90, t is about 1 or 2, R 3 is NHAc, R 4 is OH, R 8 is CMP, R 10 is 2-hydroxypropyl and m being a function of the antigen is about 1 to 10.
- a compound of Formula 101 ' is contacted with a compound of Formula 701 ' to give the corresponding product of Formula 1 g', particularly where n is about 4, p is about 90, t is about 1 or 2, R 3 is NHAc, R 4 is OH, R 8 is CMP, R 10 is 2-hydroxypropyl and m being a function of the antigen is about 1 to 10.
- compositions, pharmaceutical formulations, methods of manufacture and use of the present disclosure are the following combinations and permutations of substituent groups of Formula 1 (sub-grouped, respectively, in increasing order of preference):
- X is a foreign transplant antigen against which transplant recipients develop an unwanted immune response, a foreign antigen to which patients develop an unwanted immune response, a therapeutic protein to which patients develop an unwanted immune response, a self-antigen to which patients develop an unwanted immune response, or a tolerogenic portion thereof.
- X is a therapeutic protein to which patients develop an unwanted immune response selected from:
- X is Abciximab, Adalimumab, Agalsidase alfa, Agalsidase beta, Aldeslukin, Alglucosidase alfa, Factor VIII, Factor IX, Infliximab, L-asparaginase, Laronidase, Natalizumab, Octreotide, Phenylalanine ammonia-lyase (PAL), or Rasburicase (uricase).
- PAL Phenylalanine ammonia-lyase
- Rasburicase uricase
- X is Factor VIII, Factor IX, uricase, PAL or asparaginase.
- X is a self-antigen polypeptide selected for treating type 1 diabetes mellitus, pediatric multiple sclerosis, juvenile rheumatoid arthritis, celiac disease, or alopecia universalis.
- X is a self-antigen polypeptide selected for treating new onset type 1 diabetes mellitus, pediatric multiple sclerosis or celiac disease.
- X is a foreign antigen to which patients develop an unwanted immune response o From peanut, including conarachin (Ara h 1)
- X is a foreign transplant antigen against which transplant recipients develop an unwanted immune response, e.g. a human leukocyte antigen protein.
- X is an antibody, antibody fragment or ligand that specifically binds a circulating protein or peptide or antibody, which circulating protein or peptide or antibody gives rise to transplant rejection, immune response against a therapeutic agent, autoimmune disease, and/or allergy.
- X binds an endogenous circulating protein or peptide or antibody.
- Y is a linker selected from: Formula Ya, Formula Yb, Formula Yh, Formula Yi, Formula Yk, Formula Ym, Formula Yn, Formula Yo and Formula Yp.
- n 8 to 90 ⁇ 10%
- p 20 to 100 ⁇ 10%
- q is 3 to 20 ⁇ 3.
- n 40 to 80 ⁇ 10%
- p is 30 to 40 ⁇ 10%
- q is 4 to 12 ⁇ 3.
- Y is Formula Ya, Formula Yb, Formula Ym or Formula Yn.
- n 8 to 90 ⁇ 10%
- p 20 to 100 ⁇ 10%
- q is 3 to 20 ⁇ 3.
- n 40 to 80 ⁇ 10%
- p 30 to 40 ⁇ 10%
- q 4 to 12 ⁇ 3.
- R 8 is CMP
- R 8 is CMP
- Y is a linker selected from: Formula Yc, Formula Yf, Formula Yg and Formula Ym.
- W p is a random copolymer in which R 9 is Et-PEG t -AcN and R 10 is 2- hydroxypropyl.
- Z is galactose, galactosamine, N-acetylgalactosamine, glucose, glucosamine or N- acetylglucosamine.
- Z is galactose or N-acetylgalactosamine conjugated at C1 , C2 or C6.
- Z is galactose or N-acetylgalactosamine conjugated at C1 or C2.
- Z is N-acetylgalactosamine conjugated at C1. o Especially where Z is glucose or N-acetylglucosamine conjugated at C1 , C2 or C6. ⁇ Particularly where Z is glucose or N-acetylglucosamine conjugated at C1 or C2. • More particularly where Z is N-acetylglucosamine conjugated at C1.
- X is a self-antigen polypeptide selected for treating type 1 diabetes mellitus, pediatric multiple sclerosis, juvenile rheumatoid arthritis, celiac disease, or alopecia universalis.
- X is a self-antigen polypeptide selected for treating new onset type 1 diabetes mellitus, pediatric multiple sclerosis or celiac disease.
- Y is a linker selected from: Formula Ya, Formula Yb, Formula Yc, Formula Yf, Formula Yg, Formula Yh, Formula Yi, Formula Yk, Formula Ym, Formula Yn, Formula Yo and Formula Yp.
- W p is a W 1 polymer in which R 9 is Et-PEG t -AcN or a random copolymer in which R 9 is Et-PEG t -AcN and R 10 is 2- hydroxypropyl.
- W p is a random copolymer and includes about 30 W 1 and 60 W 2 comonomers.
- n 8 to 90 ⁇ 10%
- p 20 to 100 ⁇ 10%
- q 3 to 20 ⁇ 3.
- n 40 to 80 ⁇ 10%
- p is 30 to 40 ⁇ 10%
- q is 4 to 12 ⁇ 3.
- n 8 to 90 ⁇ 10%
- p 20 to 100 ⁇ 10%
- q is 3 to 20 ⁇ 3.
- n 40 to 80 ⁇ 10%
- p is 30 to 40 ⁇ 10%
- q is 4 to 12 ⁇ 3.
- Z is galactose, galactosamine or N- acetylgalactosamine.
- Z is galactose or N-acetylgalactosamine conjugated at C1 , C2 or C6.
- Z is galactose or N- acetylgalactosamine conjugated at C1 or C2.
- Z is glucose, glucosamine or N-acetylglucosamine.
- Z is glucose or N-acetylglucosamine conjugated at C1 , C2 or C6.
- Z is glucose or N- acetylglucosamine conjugated at C1 or C2.
- Y is a linker selected from: Formula Yc, Formula Yf, Formula Yg and Formula Ym.
- W p is a random copolymer in which R 9 is Et-PEG r AcN and R 10 is 2-hydroxypropyl.
- p is about 90 and includes about 30 W 1 and 60 W 2 comonomers.
- Y is a linker selected from: Formula Yc and Formula Ym.
- W p is a random copolymer in which R 9 is Et-PEG r AcN and R 10 is 2-hydroxypropyl.
- p is about 90 and includes about 30 W 1 and 60 W 2 comonomers.
- Z is galactose, galactosamine or N-acetylgalactosamine.
- Z is galactose or N-acetylgalactosamine conjugated at C1 , C2 or C6.
- Z is galactose or N-acetylgalactosamine conjugated at C1 or C2.
- Z is glucose, glucosamine or N-acetylglucosamine.
- Z is glucose or N-acetylglucosamine conjugated at C1 , C2 or C6.
- Z is glucose or N-acetylglucosamine conjugated at C1 or C2.
- Y is a linker selected from: Formula Ya, Formula Yb, Formula Yh, Formula Yi, Formula Yk, Formula Ym, Formula Yn, Formula Yo and Formula Yp.
- Y is a linker selected from: Formula Yc, Formula Yf, Formula Yg and Formula Ym.
- W p is a random copolymer in which R 9 is Et-PEG r AcN and R 10 is 2-hydroxypropyl.
- p is about 90 and includes about 30 W 1 and 60 W 2 comonomers.
- Y is a linker selected from: Formula Yc and Formula Ym.
- W p is a random copolymer in which R 9 is Et-PEG t -AcN and R 10 is 2-hydroxypropyl.
- p is about 90 and includes about 30 W 1 and 60 W 2 comonomers.
- n 8 to 90 ⁇ 10%
- p 20 to 100 ⁇ 10%
- q is 3 to 20 ⁇ 3.
- n 40 to 80 ⁇ 10%
- p 30 to 40 ⁇ 10%
- q 4 to 12 ⁇ 3.
- n 8 to 90 ⁇ 10%
- p 20 to 100 ⁇ 10%
- q 3 to 20 ⁇ 3.
- n 40 to 80 ⁇ 10%
- p is 30 to 40 ⁇ 10%
- q is 4 to 12 ⁇ 3.
- Z is galactose, galactosamine or N-acetylgalactosamine.
- Z is galactose or N-acetylgalactosamine conjugated at C1 , C2 or C6.
- Z is galactose or N-acetylgalactosamine conjugated at C1 or C2.
- Y is a linker selected from: Formula Yc, Formula Yf, Formula Yg and Formula Ym.
- W p is a random copolymer in which R 9 is Et- PEG,-AcN and R 10 is 2-hydroxypropyl.
- p is about 90 and includes about 30 W 1 and 60 W 2 comonomers.
- Z is glucose, glucosamine or N-acetylglucosamine.
- Z is glucose or N-acetylglucosamine conjugated at C1 , C2 or C6.
- Z is glucose or N-acetylglucosamine conjugated at C1 or C2.
- Y is a linker selected from: Formula Yc, Formula Yf, Formula Yg and Formula Ym.
- W p is a random copolymer in which R 9 is Et- PEGt-AcN and R 10 is 2-hydroxypropyl.
- p is about 90 and includes about 30 W 1 and 60 W 2 comonomers.
- Y is a linker selected from: Formula Yc and Formula Ym.
- W p is a random copolymer in which R 9 is Et- PEGt-AcN and R 10 is 2-hydroxypropyl.
- p is about 90 and includes about 30 W 1 and 60 W 2 comonomers.
- o m is 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45,
- m is from about 1 to 20.
- ⁇ m is 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22.
- m is about 10. • m is 9, 10 or 1 1.
- an integer representing a mixture including from about 1 to 100
- o n is 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 25, 30, 34, 35, 37, 40, 41 , 45, 50, 54, 55, 59, 60, 65, 70, 75, 80, 82, 83, 85, 88, 90, 95, 99, 100, 105 or 1 10.
- n is about 8 to 90.
- n is 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 25, 30, 34, 35, 37, 40, 41 , 45, 50, 54, 55, 59, 60, 65, 70, 75, 80, 82, 83, 85, 88, 90, 95 or 99.
- n is about 40 to 80.
- n is 37, 40, 41 , 45, 50, 54, 55, 59, 60, 65, 70, 75, 80, 82, 83 or 88.
- o n represents a mixture encompassing the ranges 1 -4, 2-4, 2-6, 3-8, 7-13, 6-14, 15-25, 26-30, 42-50, 46-57, 60-82, 85-90, 90-1 10 and 107-1 13.
- n represents a mixture encompassing the ranges 7-13, 6-14, 15-25, 26-30, 42-50, 46-57, 60-82, 85-90 and 82-99.
- n represents a mixture encompassing the ranges 36- 44, 42-50, 46-57, 60-82 and 75-85.
- o p is an integer representing a mixture including from about 2 to 150.
- ⁇ p is 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 70, 75, 80, 85, 90, 95, 100, 1 10, 120, 130, 140, 150, 160 or 165.
- n is an integer representing a mixture including from about 1 to 100.
- n is 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 25, 30, 34, 35, 37, 40, 41 , 45, 50, 54, 55, 59, 60, 65, 70, 75, 80, 82, 83, 85, 88, 90, 95, 99, 100, 105 or 1 10.
- n is about 8 to 90.
- n 8 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19,
- n is about 40 to 80.
- n is 37, 40, 41 , 45, 50, 54, 55, 59, 60, 65, 70, 75, 80, 82, 83 or 88.
- p is 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 70, 75, 80, 85, 90, 95, 100 or 110.
- n is an integer representing a mixture including from about 1 to 100.
- n is 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13,
- n is about 8 to 90.
- n is 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 25, 30, 34, 35, 37, 40, 41 , 45, 50, 54, 55, 59, 60, 65, 70, 75, 80, 82, 83, 85, 88, 90, 95 or 99.
- n is about 40 to 80.
- n 37, 40, 41 , 45, 50, 54, 55, 59, 60, 65, 70, 75, 80, 82, 83 or 88.
- p is 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, or 44.
- n is 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 25, 30, 34, 35, 37, 40, 41 , 45, 50, 54, 55, 59, 60, 65, 70, 75, 80, 82, 83, 85, 88, 90, 95, 99, 100, 105 or 1 10.
- n is about 8 to 90.
- n is 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 25, 30, 34, 35, 37, 40, 41 , 45, 50, 54, 55, 59, 60, 65, 70, 75, 80, 82, 83, 85, 88, 90, 95 or 99.
- n is about 40 to 80.
- n 37, 40, 41 , 45, 50, 54, 55, 59, 60, 65, 70, 75, 80, 82, 83 or 88.
- o q is an integer representing a mixture including from about 1 to 44.
- ⁇ q is 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 44 or 48.
- compositions of the disclosure find use in a variety of applications including, as will be appreciated by those in the art, treatment of transplant rejection, immune response against a therapeutic agent, autoimmune disease, and food allergy, among other uses.
- compositions of the disclosure are used to modulate, particularly down-regulate, antigen-specific undesirable immune response.
- compositions of the disclosure are useful, in additional embodiments, to bind and clear from the circulation specific undesired proteins, including antibodies endogenously generated in a patient (i.e., not exogenous antibodies administered to a patient), peptides and the like, which cause autoimmunity and associated pathologies, allergy, inflammatory immune responses, and anaphylaxis.
- antigens are targeted to the liver for presentation via antigen-presenting cells to specifically down-regulate the immune system or for clearance of unwanted circulating proteins.
- This is distinct from previous uses of liver targeting, for example as described in US 2013/0078216, where the purpose of liver-targeting molecules such as DOM26h-196-61 was the delivery of therapeutic agents to treat liver diseases such as fibrosis, hepatitis, Cirrhosis and liver cancer.
- compositions and methods to treat unwanted immune response to self-antigens and foreign antigens including but not limited to: a foreign transplant antigen against which transplant recipients develop an unwanted immune response (e.g., transplant rejection), a foreign antigen to which patients develop an unwanted immune (e.g., allergic or hypersensitivity) response, a therapeutic agent to which patients develop an unwanted immune response (e.g., hypersensitivity and/or reduced therapeutic activity), a self-antigen to which patients develop an unwanted immune response (e.g., autoimmune disease)
- Autoimmune disease states that can be treated using the methods and compositions provided herein include, but are not limited to: Acute Disseminated Encephalomyelitis (ADEM); Acute interstitial allergic nephritis (drug allergies); Acute necrotizing hemorrhagic leukoencephalitis; Addison's Disease; Alopecia areata; Alopecia universalis; Ankylosing Spondylitis; Arthritis, juvenile; Arthritis, psoriatic; Arthritis, rheumatoid; Atopic Dermatitis; Autoimmune aplastic anemia; Autoimmune gastritis; Autoimmune hepatitis; Autoimmune hypophysitis; Autoimmune oophoritis; Autoimmune orchitis; Autoimmune polyendocrine syndrome type 1 ; Autoimmune polyendocrine syndrome type 2; Autoimmune thyroiditis; Behcet's disease; Bronchio
- a particular group of autoimmune disease states that can be treated using the methods and compositions provided herein include, but are not limited to: Acute necrotizing hemorrhagic leukoencephalitis; Addison's Disease; Arthritis, psoriatic; Arthritis, rheumatoid; Autoimmune aplastic anemia; Autoimmune hypophysitis; Autoimmune gastritis; Autoimmune polyendocrine syndrome type 1 ; Bullous pemphigoid; Celiac disease; Coxsackie myocarditis; Dermatitis herpetiformis Duhring; Diabetes mellitus (Type 1); Epidermolysis bullosa acquisita; Giant cell myocarditis; Goodpasture's syndrome; Graves' disease; Hashimoto's thyroiditis; Mixed connective tissue disease; Multiple sclerosis; Myasthenia gravis; Neuromyelitis optica; Pernicious angemis; Pemphigus vulgaris
- treatment can be provided for reactions against, for example: peanut, apple, milk, egg whites, egg yolks, mustard, celery, shrimp, wheat (and other cereals), strawberry and banana.
- a patient can be tested to identify a foreign antigen against which an unwanted immune response has developed, and a composition of the disclosure can be developed based on that antigen.
- compositions and methods of the disclosure specificity in binding to antigen-presenting cells in the liver (particularly binding to hepatocytes and specifically ASGPR) should initially be determined. This can be accomplished, for example, by employing a marker (such as the fluorescent marker phycoerythrin ("PE")) in a composition of the disclosure.
- PE fluorescent marker
- the composition is administered to suitable experimental subjects. Controls, e.g., unconjugated PE or vehicle (saline) are administered to other group(s) of subjects.
- the composition and controls are allowed to circulate for a period of 1 to 5 hours, after which the spleens and livers of the subjects are harvested and measured for fluorescence. The specific cells in which fluorescence is found can be subsequently identified.
- Compositions of the disclosure when tested in this manner, show higher levels of concentration in the antigen-presenting cells of the liver as compared with unconjugated PE or vehicle.
- Effectiveness in immune modulation can be tested by measuring the proliferation of OT-I CD8 + cells (transplanted into host mice) in response to the administration of a composition of the disclosure incorporating a known antigen, such as ovalbumin ("OVA"), as compared with administration of the antigen alone or just vehicle.
- Compositions of the disclosure when tested in this manner, show an increase of OT-I cell proliferation as compared with antigen alone or vehicle, demonstrating increased CD8+ T-cell cross-priming.
- the proliferating OT-I CD8 + T cells can be phenotypically analyzed for molecular signatures of exhaustion [such as programmed death-1 (PD-1 ), FasL, and others], as well as Annexin-V binding as a hallmark of apoptosis and thus deletion.
- the OT-I CD8 + T cells can also be assessed for their responsiveness to an antigen challenge with adjuvant in order to demonstrate functional non-responsiveness, and thus immune tolerance, towards the antigen. To do so, the cells are analyzed for inflammatory signatures after administration of compositions of the disclosure into host mice followed by an antigen challenge. Compositions of the disclosure when tested in this manner demonstrate very low (e.g., background) levels of inflammatory OT-I CD8 + T cell responses towards OVA in comparison to control groups, thus demonstrating immune tolerance.
- Humoral immune response can be tested by administering a composition of the disclosure incorporating a known antigen, such as OVA, as compared with the administration of the antigen alone or just vehicle, and measuring the levels of resulting antibodies.
- Compositions of the disclosure when tested in this manner show very low (e.g. , background) levels of antibody formation responsive to their administration and the administration of vehicle, with significantly higher levels of antibody formation responsive to administration of the antigen.
- compositions of the disclosure when tested in this manner show low levels of antibody formation responsive to challenge with the antigen in groups pretreated with such compositions as compared to groups that are not pretreated.
- NOD non-obese diabetic
- EAE experimental autoimmune encephalomyelitis
- the NOD mouse develops spontaneous autoimmune diabetes (similar to type 1 a diabetes in humans).
- Groups of NOD mice are treated with test compound or a negative control, followed by measurement of blood glucose.
- Successful treatment corresponds to likelihood of treating diabetes in humans or proof of mechanism for approaches to the treatment of other autoimmune diseases. (See, e.g., Anderson and Bluestone, Annu. Rev. Immunol. 2005;23:447-85.)
- compositions of the disclosure are administered at a therapeutically effective dosage, e.g., a dosage sufficient to provide treatment for the disease states previously described.
- Administration of the compounds of the disclosure or the pharmaceutically acceptable salts thereof can be via any of the accepted modes of administration for agents that serve similar utilities.
- human dosage levels have yet to be optimized for the compounds of the disclosure, these can initially be extrapolated from the about 10 pg to 100 pg doses administered for mice.
- an individual human dose is from about 0.01 to 2.0 mg/kg of body weight, preferably about 0.1 to 1.5 mg/kg of body weight, and most preferably about 0.3 to 1.0 mg/kg of body weight.
- Treatment can be administered for a single day or a period of days, and can be repeated at intervals of several days, one or several weeks, or one or several months. Administration can be as a single dose (e.g., as a bolus) or as an initial bolus followed by continuous infusion of the remaining portion of a complete dose over time, e.g., 1 to 7 days.
- the amount of active compound administered will, of course, be dependent on any or all of the following: the subject and disease state being treated, the severity of the affliction, the manner and schedule of administration and the judgment of the prescribing physician. It will also be appreciated that amounts administered will depend upon the molecular weight of the antigen, antibody, antibody fragment or ligand as well as the size of the linker.
- compositions of the disclosure can be administered either alone or in combination with other pharmaceutically acceptable excipients. While all typical routes of administration are contemplated (e.g. oral, topical, transdermal, injection (intramuscular, intravenous, or intra-arterial)), it is presently preferred to provide liquid dosage forms suitable for injection.
- the formulations will typically include a conventional pharmaceutical carrier or excipient and a composition of the disclosure or a pharmaceutically acceptable salt thereof.
- compositions can include other medicinal agents, pharmaceutical agents, carriers, and the like, including, but not limited to the therapeutic protein, peptide, antibody or antibody-like molecule corresponding to the antigen (X) employed in the composition of the disclosure, and other active agents that can act as immune-modulating agents and more specifically can have inhibitory effects on B-cells, including anti-folates, immune suppressants, cyostatics, mitotic inhibitors, and anti-metabolites, or combinations thereof.
- active agents that can act as immune-modulating agents and more specifically can have inhibitory effects on B-cells, including anti-folates, immune suppressants, cyostatics, mitotic inhibitors, and anti-metabolites, or combinations thereof.
- the pharmaceutically acceptable composition will contain about 0.1 % to 95%, preferably about 0.5% to 50%, by weight of a composition of the disclosure, the remainder being suitable pharmaceutical excipients, carriers, etc. Dosage forms or compositions containing active ingredient in the range of 0.005% to 95% with the balance made up from non-toxic carrier can be prepared.
- Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. an active composition of the disclosure (e.g. , a lyophilized powder) and optional pharmaceutical adjuvants in a carrier, such as, for example, water (water for injection), saline, aqueous dextrose, glycerol, glycols, ethanol or the like (excluding galactoses), to thereby form a solution or suspension.
- a carrier such as, for example, water (water for injection), saline, aqueous dextrose, glycerol, glycols, ethanol or the like (excluding galactoses)
- the pharmaceutical composition to be administered can also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, stabilizing agents, solubilizing agents, pH buffering agents and the like, for example, sodium acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine acetate and triethanolamine oleate, etc., osmolytes, amino acids, sugars and carbohydrates, proteins and polymers, salts, surfactants, chelators and antioxidants, preservatives, and specific ligands.
- auxiliary substances such as wetting agents, emulsifying agents, stabilizing agents, solubilizing agents, pH buffering agents and the like, for example, sodium acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine acetate and triethanolamine oleate, etc., osmolytes, amino acids, sugars and carbohydrates, proteins and polymers, salts, surfactants,
- F1aA-OVA-m 4 -n 80 (or F1 a-OVA-m 4 -n 80 -2NGAL)
- galactosamine (10.0 mg, 0.04638 mmol) was dissolved with stirring in 100 ⁇ of pH 8.0 PBS containing 5 mM EDTA.
- Pyridyl dithiol-poly(ethylene glycol)-NHS ester (Formula 104 where n is 80) (16.23 mg, 0.00464 mmol) dissolved in 100 ⁇ of pH 7.0 PBS was added to the stirring solution of galactosamine. After 1 hour, the resulting pyridyl dithiol-poly(ethylene glycol)-N- acetylgalactosamine (Formula 106A) was ready to be used without further purification.
- X Insulin (SEQ ID NO:1) and m is 2,
- X is MBP13-32 (SEQ ID NO:7) and m is 1,
- X is MBP111-129 (SEQ ID NO:9) and m is 1,
- X Tyrosinase (SEQ ID NO: 15) and m is 8,
- X is Aquaporin-4 (SEQ ID NO:17) and m is 4,
- X is S-arrestin (SEQ ID NO: 18) and m is 12,
- X is Alpha-gliadin "33-mer” native (SEQ ID NO:20) and m is 1 ,
- X Alpha-gliadin (SEQ ID NO:22) and m is 1,
- X Omega-gliadin (SEQ ID NO:23) and m is 1 ,
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/859,292 US10946079B2 (en) | 2014-02-21 | 2015-09-19 | Glycotargeting therapeutics |
US15/185,564 US10046056B2 (en) | 2014-02-21 | 2016-06-17 | Glycotargeting therapeutics |
PCT/IB2016/001411 WO2017046652A1 (en) | 2015-09-19 | 2016-09-16 | Glycotargeting therapeutics |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3349784A1 true EP3349784A1 (en) | 2018-07-25 |
Family
ID=57121450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16778870.2A Withdrawn EP3349784A1 (en) | 2015-09-19 | 2016-09-16 | Glycotargeting therapeutics |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP3349784A1 (en) |
JP (2) | JP7082045B2 (en) |
KR (1) | KR20180080195A (en) |
CN (1) | CN108430497B (en) |
AU (2) | AU2016325073B2 (en) |
BR (1) | BR112018005409A2 (en) |
CA (1) | CA2998066A1 (en) |
EA (1) | EA036102B9 (en) |
HK (1) | HK1257845A1 (en) |
IL (2) | IL306015A (en) |
MX (1) | MX2018003411A (en) |
WO (1) | WO2017046652A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
CN108117586A (en) | 2010-08-10 | 2018-06-05 | 洛桑聚合联合学院 | Erythrocyte binding therapeutic agent |
US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
JP6744227B2 (en) | 2014-02-21 | 2020-08-19 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) | Sugar-targeted therapeutic agent |
US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
CN108430497B (en) * | 2015-09-19 | 2024-05-07 | 洛桑聚合联合学院 | Sugar-targeted therapeutic agents |
WO2018232176A1 (en) | 2017-06-16 | 2018-12-20 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
IL278538B2 (en) * | 2018-05-09 | 2024-01-01 | Univ Chicago | Compositions and methods concerning immune tolerance |
CN111214461B (en) * | 2020-03-24 | 2021-04-16 | 河南大学 | Preparation and application of sugar-targeted modified siRNA (small interfering ribonucleic acid) nanoparticles |
CN116819072B (en) * | 2023-08-28 | 2023-11-17 | 迪亚莱博(张家港)生物科技有限公司 | Antigen protein composition for detecting anti-AQP 4 autoantibody and chemiluminescent detection kit |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006002382A2 (en) * | 2004-06-24 | 2006-01-05 | The Scripps Research Institute | Arrays with cleavable linkers |
WO2011086143A2 (en) * | 2010-01-14 | 2011-07-21 | Glaxo Group Limited | Liver targeting molecules |
US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
CN108117586A (en) | 2010-08-10 | 2018-06-05 | 洛桑聚合联合学院 | Erythrocyte binding therapeutic agent |
US8501930B2 (en) * | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
CN103582496B (en) * | 2011-06-03 | 2016-05-11 | 3M创新有限公司 | There is the Heterobifunctional connection base of polyethylene glycol segment and the immune response modifier conjugate of being made by it |
ES2781773T3 (en) * | 2012-02-15 | 2020-09-07 | Ecole Polytechnique Fed Lausanne Epfl | Erythrocyte binding therapeutics |
MX2015001678A (en) * | 2012-08-09 | 2015-08-14 | Roche Glycart Ag | Asgpr antibodies and uses thereof. |
JP6744227B2 (en) * | 2014-02-21 | 2020-08-19 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) | Sugar-targeted therapeutic agent |
CN108430497B (en) * | 2015-09-19 | 2024-05-07 | 洛桑聚合联合学院 | Sugar-targeted therapeutic agents |
-
2016
- 2016-09-16 CN CN201680064903.3A patent/CN108430497B/en active Active
- 2016-09-16 WO PCT/IB2016/001411 patent/WO2017046652A1/en active Application Filing
- 2016-09-16 IL IL306015A patent/IL306015A/en unknown
- 2016-09-16 CA CA2998066A patent/CA2998066A1/en active Pending
- 2016-09-16 EP EP16778870.2A patent/EP3349784A1/en not_active Withdrawn
- 2016-09-16 EA EA201890778A patent/EA036102B9/en unknown
- 2016-09-16 IL IL257958A patent/IL257958B2/en unknown
- 2016-09-16 JP JP2018514285A patent/JP7082045B2/en active Active
- 2016-09-16 MX MX2018003411A patent/MX2018003411A/en unknown
- 2016-09-16 KR KR1020187010936A patent/KR20180080195A/en not_active Application Discontinuation
- 2016-09-16 AU AU2016325073A patent/AU2016325073B2/en active Active
- 2016-09-16 BR BR112018005409A patent/BR112018005409A2/en active Search and Examination
-
2019
- 2019-01-07 HK HK19100202.3A patent/HK1257845A1/en unknown
-
2021
- 2021-10-22 JP JP2021173077A patent/JP7434248B2/en active Active
-
2023
- 2023-06-02 AU AU2023203475A patent/AU2023203475A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2018003411A (en) | 2018-09-06 |
EA036102B1 (en) | 2020-09-29 |
JP2018532722A (en) | 2018-11-08 |
AU2016325073B2 (en) | 2023-03-16 |
CN108430497A (en) | 2018-08-21 |
BR112018005409A2 (en) | 2018-10-09 |
IL257958B2 (en) | 2024-02-01 |
CA2998066A1 (en) | 2017-03-23 |
AU2016325073A1 (en) | 2018-04-05 |
JP7434248B2 (en) | 2024-02-20 |
IL257958A (en) | 2018-06-28 |
JP2022028673A (en) | 2022-02-16 |
JP7082045B2 (en) | 2022-06-07 |
EA036102B9 (en) | 2020-12-30 |
HK1257845A1 (en) | 2019-11-01 |
WO2017046652A1 (en) | 2017-03-23 |
CN108430497B (en) | 2024-05-07 |
IL306015A (en) | 2023-11-01 |
IL257958B1 (en) | 2023-10-01 |
AU2023203475A1 (en) | 2023-06-29 |
EA201890778A1 (en) | 2018-08-31 |
KR20180080195A (en) | 2018-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016325073B2 (en) | Glycotargeting therapeutics | |
US11793882B2 (en) | Glycotargeting therapeutics | |
US11801305B2 (en) | Glycotargeting therapeutics | |
US11666638B2 (en) | Glycotargeting therapeutics | |
US11654188B2 (en) | Glycotargeting therapeutics | |
JP2024063005A (en) | Glyco-targeting therapeutics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180411 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20190506 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1257845 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20240228 |